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· ABSTRACT 

The association of mucus and mucin hypersecretion with respiratory diseases such as 
COPD, cystic fibrosis and asthma has long been known. The role of the dominant 
respiratory mucins (MUC5AC and MUC5B) and MUC2 has been investigated in chronic 
airway diseases as it is the mucin glycoprotein that confers upon mucus its biological, 
rheological and physicochemical properties. Tuberculosis (TB) is a highly contagious 
respiratory disease that spreads via the pathogen Mycobacterium tuberculosis. TB is 
associated with diseases such as bronchiectasis and bronchorrhea whereby copious 
amounts of sputum (diseased mucus) are produced. According to the World Health 
Organization (WHO), stringent methods are required to curb the spread of TB as the HIV 
pandemic and the demographics of varying infected populations are strongly influencing 
the transmission and lack of resistance to TB. Within South Africa, specifically the 
Western Cape, TB has wreaked havoc especially amongst those of the lower socio­
economic groups. However, despite the prevalence of the disease in South Africa and the 
known morbidity and mortality associated with mucus and mucin hypersecretion in 
respiratory diseases, little is known of the association between respiratory mucins and 
TB. 
This is a novel study that investigated the association between respiratory mucins and TB 
at a biochemical and molecular level. . The biochemical study involved the collection of 
sputum from healthy individuals, post mortem cadavers and suspected TB positive adults 
and children. Antibody detection was carried out on of crude mucin samples as it was 
proven unnecessary to purify the samples via CsCI ultracentrifugation. This resulted in a 
substantial reduction in expense and time as CsCI purification is a lengthy, expensive 
procedure. 
MUC5B was identified in both the healthy controls and TB positive adults and children. 
In contrast MUC5AC was barely evident in the controls but presented in both the TB 
positive adults and children. MUC2 barely featured in the control group but was 
identified as glycoforms in the TB positive adults and children. The low charge doublet 
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glycoform appeared more distinctly in the 'possible' TB state and the high charge smear 
appeared more distinctly in the probable to definite TB stage. MUC5AC and MUC5B 
did not present as glycoforms. 
An amino acid analysis presented with high values of glycine, threonine, serine, proline 
and alanine in the healthy controls. This was suggestive of a typical mucin amino acid 
profile. The combination of glycine, threonine, serine, proline and alanine were much 
lower in the PM group and TB adults and children. Differences in the amino acid 
composition were related to differences in the level of secretion of varying mucin types 
during a healthy and diseased state. The individual serine, threonine and proline values 
did not dominate the composition of the protein backbone. This was explained by 
incomplete deglycosylation prior to amino acid analysis. The combined serine, threonine 
and proline (STP) content and the serine and threonine combination predominated in the 
healthy volunteers (22.38 mol%). The TB positive adults and children presented with 
lower yet similar results (18.37 mol% and 17.17 mol% respectively). It is likely that the 
minor differences between the control group and TB positive group could be secondary 
to the TB mycobacteriums interaction with the sugar side chains. 
In addition, molecular investigations were undertaken for the presence of known 
polymorphisms in the mucin genes, MUC2 and MUC5B, and the informativity of such 
polymorphisms in the South African population. Both the MUC2IPvuII polymorphism in 
exon 11 of the MUC2 gene and the VNTR of intron 36 of MUC5B were identified in the 
study sample. Generally the polymorphic C allele of MUC2IPvuII occurred less 
frequently than the G allele. Categorisation of the 'sample on the basis of TB status 
showed a higher C allele frequency in TB positive cases and revealed that allele C 
homozygotes were found only amongst TB positive cases (30%). 
The MUC5B alleles represented variable numbers of the 59bp repeat sequence within 
intron 36. This differed from the European study as a greater number of repeats were 
identified in the Western Cape population. In comparison to the European study of 
Dessyn et al (1999) it appeared that the frequency of the 8 repeating unit was higher in 
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the Western Cape population whereas the 7 repeating unit dominated in the European 
population. Furthermore the 10 and 3 repeating unit f?und of this study did not present in 
the European study, and the 4 repeating unit of the European study was absent in this 
study group. The 10 repeating unit was' of interest as it was seen only in a TB negative 
individual and not in the TB positive group. The 8/8 allele combination common to the 
study group presented predominantly in the TB positive individuals. 
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CHAPTER ONE 
INTRODUCTION 
1.1 Mucus secretions and distribution 
Mucus has played significant roles in the vertebrate and invertebrate kingdom. This 
sticky, visco-elastic gel has served man and animals throughout the evolutionary process 
as the primary line of defence against both external and internal irritants (Moniaux et ai., 
2001, Davies et ai., 2002, Rose and Voynow, 2006). It has acted as a lubricant 
preventing dessication in slugs, snails and earthworms· (Negus, 1967) and has assisted 
amphibians and eels during respiration by allowing for gaseous exchange through the 
skin. It has further served invertebrates by acting as a distasteful external coating 
protecting them from predators and is known to have antibacterial properties in the 
secretions of oysters and acorn worms. Slugs have exploited the gel-sol properties of 
mucus thereby allowing for their motility (Denny, 1989) and a mucus layer in the frog 
palate allows, via the beating of cilia, for the movement of food to its gastrointestinal 
tract (Silberberg et al., 1977). Mucus also provides nutrition to lower life forms. This 
situation is evident when organic material is trapped in the caudal mucus plug of a slug 
(Denny, 1989). With respect to more evolved life forms, such as man, mucus is found to 
lubricate the epithelial lining of the gastrointestinal, genitourinary and respiratory tracts 
(Taylor et al., 2005). It has also been found in reduced quantities in the middle ear and 
lachrymal glands (Fitzgerald et ai., 1987) and in a soluble form in human gallbladder bile 
(Pearson et al., 1982). 
1.2 The general role of mucus 
Mucus a crude native secretion primarily protects the internal tracts of the body creating 
an interface or barrier between the epithelial surfaces within the host and its internal 
agents and the external environment. It is further specialised in function depending on 
the organ within which it is found. 
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1.2.1 Gastric mucus 
A thick, stable layer of unstirred mucus lines the gastric epithelia and in doing so shields 
the mucosa (Venables, 1986) from strong acids, proteases and the injurious action of food 
or foreign material (Gevers, 1987, Allen and Fiemstrom, 2005, Taylor et ai., 2005). The 
mucus bicarbonate barrier in particular is responsible for the neutralization of luminal 
acid and acts as a barrier to pepsin digestion of the underlying gastric epithelia (Allen and 
Fiemstrom, 2005). Degraded gastric mucus in the gastric juices, serves to enhance the 
lubrication of food particles and gastric mucins buffer the stomach against a drop in pH 
and proteolytic enzymes (Taylor et al., 1998). 
1.2.2 Intestinal mucus 
Intestinal mucus acts as a barrier to invasion by pathogenic micro-organisms by 
interacting with, aggregating or binding bacteria. It is known to increase in volume, in 
response to the presence of toxins and parasites, preventing them from attaching to sites 
on the epithelial lining (Neutra et al., 1987). IgA within intestinal mucus is known to act 
as a barrier to Candida colonisation (Bai et aI., 2004). Mucin carbohydrate side chains of 
the insoluble mucus barrier are hypothesized to compete with pathogens for epithelial 
sites hence minimising or preventing colonisation (Allen et al., 1990). The mucus barrier 
further serves to protect the colonic epithelium against mechanical injury (Taylor et al., 
2005) from hard faecal matter and provides a conducive environment and food source for 
natural colonic bacteria (Hoskins, 1978). 
1.2.3 Gallbladder mucus 
Mucus of the gallbladder protects the epithelium from the action of surface active 
chemicals (Gevers, 1987). Biliary mucins are suspected to be involved in the formation 
of gallstones. These mucins are located in the centre of gallstones and are believed to 
participate in the initial phase of gallstone development by a possible hydrophobic 
binding to cholesterol or interfering with the removal of seed crystals from the 
gallbladder (Baeckstrom, 1994). 
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1.2.4 Cervical mucus 
The viscosity, water and protein composition of cervical mucus alters depending on the 
phase of the menstrual cycle (van Kooij et ai, 1980). The levels of the hormones 
progesterone and oestrogen also vary during the menstrual cycle. These changes play 
vital roles during fertilization as the motility of spermatozoa is dependent on the 
viscoelasticity of the cervical mucus and the level of two hormones (Yurewicz et at., 
1987, Argueso et at., 2002). During ovulation, oestrogen increases resulting in a more 
hydrated and less viscous mucus solution which is conducive to the transportation of 
spermatozoa. The reduction in viscosity could be attributed to the hydrophilic nature of 
mucin carbohydrates, which increase during the ovulatory phase and in doing so retain 
water in the endocervix (Wiggins et at., 2001, Argueso et al., 2002). The luteal phase 
results in the dominance of progesterone hence a less hydrated, more viscous mucus gel 
which greatly reduces the motility of the spermatozoa through the cervical mucus plug 
(Wolf et ai., 1977, Wiggins et ai., 2001). 
1.2.5 Salivary mucus 
Mucus assists in the mastication of food allowing for bolus formation (Gevers, 1987). 
Salivary mucins confer upon mucus its antimicrobial properties. They also behave as 
competitors for receptors on the buccal epithelium attempting to reduce colonisation by 
Streptococci. With the assistance of secretory IgA, salivary mucins serve to trap and 
aggregate infecting organisms (Kashket et ai., 1972, Bobek and Situ, 2003) hence 
allowing for phagocytosis by macrophages, the products of which are washed away by 
saliva (Neutra et ai., 1987). They are known to interact with and trap respiratory, 
cariogenic, and periodontal pathogens as well as Candida albicans and HSV and HIV-1 
viruses. It has been proposed that human salivary mucin, MUC7, poses as a potent agent 
for antifungal therapy (Situ et al., 2003, Wei and Bobek, 2005). 
1.2.6 Respiratory Mucus 
Tracheobronchial secretions exist in a gel and sol phase indicative of a double layer of 
mucus (Kim, 1997). The sol phase, in a normal state, forms a 2-5~ thick blanket that 
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extends from the alveoli to the trachea (Kaliner et aI., 1986). The gel phase (or 
superficial blanket) traps airway irritants allowing for their easy removal with the beating 
of cilia which exist within the sol phase (Gevers, 1987, Kim, 1997). This is termed 
mucociliary clearance and is one of the various roles of airway mucus (Leikauf et al., 
2002). It was hypothesized that the mucus blanket acts as a barrier preventing the 
transudation of the serum through the mucosa (Negus 1963, Negus 1967, Rogers, 2005). 
Respiratory mucus further defends the airways as a lubricant, humidifier, a barrier to 
destructive foreign organisms, and a neutralizing agent against toxic gases and provides a 
site for immunoglobulin action. This tenacious viscoelastic slime sterns from the goblet 
cells of the respiratory tree (to the level of the alveolar ducts) and submucosal glands of 
the respiratory tract (which exists' between the nose and the cartilaginous sector of the 
airways). 
1.3 Composition of respiratory mucus 
Mucus in general is a mixture of secreted proteins such as immunoglobulin A, lactoferrin, 
lysozyme and transudated proteins specifically albumin (Gevers, 1987). Water makes up 
95% of mucus, salts and dialyzable components are approximately 1 % and free proteins 
and mucin glycoproteins are in the 0.5-1 % range. In airway diseases, mucus is 
comprised of the above mentioned components together with dead bacteria and 
leucocytes, DNA and lipids (Creeth, 1978, Kim, 1997). The water content of mucus is of 
paramount importance to the functioning of the mucus blanket. It has been illustrated 
that dehydration in birds resulted in a thicker more condensed mucus blanket which lead 
to a reduction in efficiency in particle transport of the nasal mucosa. A similar situation 
was discovered in dehydrated patients with chronic obstructive lung disease. 
Rehydration was found to clear the respiratory tract and reduce the viscosity of the 
sputum (Yeager, 1971). Immunoglobulins, specifically IgA, assist in immune function. 
IgG and IgM are also present in mucus secretions but IgA appears to play the pivotal role 
as it protects against various infections. Immunoglobulin IgE has been associated with 
anergic bronchial asthma and a lack thereof may increase ones susceptibility to 
infections. In general it appears that mucosal antibodies afford antimicrobial protection 
against various recurring infections. The antimicrobial activity of the mucus blanket is 
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further strengthened by the action of lactoferrin and lysozyme. Lactoferrin chelates iron 
thereby preventing bacterial growth and lysozyme hydrolyzes bacterial cell walls 
(Yeager, 1971). 
Sputum, a pathological form of respiratory mucus, consists of bronchial mucus together 
with saliva, transudated serum proteins and inflammatory and desquamated epithelial 
cells (Kim, 1997). Investigations into nonpurulent chronic bronchitis sputa revealed the 
presence of various mucin glycoproteins in the gel phase (Davies et al., 2002, Yeager, 
1971). Mucins are considered the main components of mucus as they confer upon mucus 
its rheological and physicochemical properties. 
1.4 Structure and composition of mucins 
Mucins determine the viscoelasticity of mucus and in tum determine the mucociliary 
action of the mucus blanket (Rogers, 2004). They are high molecular weight 
glycoproteins which range in size from a hundred to several thousand kilodaltons. 
Structurally they are composed of a peptide backbone or apomucin which is heavily 
glycosylated with O-linked oligo saccharides (50-80% of the mucin weight) (Figure 1.1) 
(Voynow,2002). The composition and length of the oligosaccharides determines the size 
and charge density and thus the heterogeneity of mucins (Kim et aI., 2003). The 
apomucin does have nonglycosylated regions which appear rich in cysteine. This is 
indicative of either inter or intra molecular disulphide bonding which results in the mucin 
polymers (Figure 1.1). The glycosylated regions have been described as taking on a 
bottle brush structure; the oligosaccharides represent the bristles and the apomucin the 
wire support (McLeod, 1992). Mucins, depending on the investigators, have been 
illustrated as two separate models. The windmill model, proposed by Allen (1978), 
claims that mucins are lengthened rod like structures that polymerize to form larger rods 
representative of windmills; which at high concentrations form a viscoelastic gel (Gevers, 
1987). This structure was challenged by Carlstedt and Sheehan (1984) who proposed that 
mucins are linear peptides containing glycosylated and non-glycosylated regions which 
alternate to form subunits. These subunits are held together by disulphide bonds which 
result in flexible structures (McLeod, 1992). Electron microscopy of purified bronchial 
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mucins describes them as being "extended filamentous polypeptides which are somewhat 
stiffened by the presence of numerous carbohydrate side chains" (Slayter et ai., 1984). 
-<OIigos:;cdlaride Sde Chain 
o Amino AcidJ 
@ Seooe 
® Tmeontne 
o Sug3 n> 
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\."\ 
I I 
, I 
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Figure 1.1 A schematic diagram of a human mucin glycoprotein illustrating the 
protein backbone and carbohydrate side-chains. The circles represent amino acids that 
make up the apomucin. Theonine and serine are the points at which O-glycosylation takes place 
within the tandem repeat. (-S-S-) represents inter and intra chain disulfide linkages. (Kaliner et 
al., 1986). 
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1.4.1 Carbohydrate side chains 
Human mucins in general comprise of the monosaccharides fucose, galactose, N­
acetylneuraminic acid (sialic acid), N-acetylglucosamine and N-acetylgalactosamine. 
Each oligosaccharide varies in length between 1-20 monosaccharides. The terminal ends 
of oligo saccharides are identified by the presence of fucose, galactose, N­
acetylneuraminic acid and N-acetylglucosamine (Lamblin et al., 2001). The O-linked 
glycoproteins, specifically secreted or membrane proteins, are identified by an lX-:-linkage 
ofN-acetylgalactosamine to the hydroxylated amino acids serine or threonine (Piller and 
Piller, 1993, Carlson, 1977). N-acetylgalactosamine attaches specifically to the serine or 
threonine amino acids of the apomucin (Carlson, 1977). These types of O-glycans 
constitute approximately 90% ofmucins (Piller and Piller, 1993). 
The function of O-linked sugars remains unknown but it is speculated that they are 
involved in the secondary structure of heavily glycosylated glycoproteins (Piller and 
Piller, 1993). The presence of N-acetylgalactosamine alone results in the mucin 
polypeptide unfolding from a globular conformation to a linear structure. This extended, 
linear conformation in tum is vital for the gel formation of mucins, hence adding to their 
protective, hydrating nature (Hayase et al., 1993, Piller and Piller, 1993). Sialic acids, 
'specifically N-acetylneuraminic are biologically significant constituents of mucins 
(Spyridaki et al., 1996). Sialic acid together with sulphate is responsible for the acidic 
nature of bronchial mucins as well as their negative charge (Kaliner et al., 1986). 
Histochemical investigations have highlighted increases in the amounts of sulphated 
mucins during airway diseases (Buisine et al., 1999). Bronchial mucins are highly 
glycosylated with marked heterogeneity which is resultant of the variation in 
oligosaccharide length, composition, structure, branching and acidity. This heterogeneity 
was illustrated when 88 varying carbohydrate chains were isolated from respiratory 
mucins of a single individual of blood type O. The terminal ends of human airway 
mucins also appear to have special features as they can act as receptors for various cells 
of the airway; the terminal sugar NeuAca2-3Gal,81-3GaINAc behaves as a receptor for 
macrophage sialoadhesin. Airway mucin carbohydrates appear to present with epitopes 
that are possible sites of attachment for microbes and viruses. In providing such an 
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attachment they are believed to protect underlying mucosae (Lamblin et al., 2001, 
Voynow, 2002). 
1.4.2 Peptide backbone 
The apomucin is a product ofMUC genes (Rose et al., 2001). It is approximately 20% of 
the glycoprotein and is comprised primarily of the amino acids proline, threonine and 
serine (PTS) (Kaliner et al., 1986). O-glycosylated mucins share a common protein core 
which is characterised by a tandem repeat rich in PTS' s (Rose et al., 2001). The tandem 
repeat is the largest domain or region (Moniaux et at., 2001) within a mucin molecule 
and is the site at which O-glycosylation takes place (Hovenberg et at., 1997). The 
tandem repeat along with its O-glycans determines the size, mass and shape of mucins 
adding to their rheological, biological and physicochemical properties of mucins (Rose 
and Voynow, 2006). Due to heavy glycosylation these regions are protease resistant 
(Perini et at., 1989). The non-glycosylated or naked regions are rich in cysteine 
(Wickstrom et al., 1998) as they represent the disulphide bonds which hold the mucin 
subunits together. In addition to the PTS, human bronchial mucins are further dominated 
by glycine and alanine which altogether account for 50-60% of the protein backbone 
(Bhattacharyya et at., 1990). 
Apomucins vary according to the "amino acid sequence, the size and number of repeats 
between MUC genes and differs between human and rodent homologues of the same 
MUC gene". The varying and unique amino acid sequences determine the pattern of 0­
glycosylation, hence the heterogeneity between mucins (Voynow, 2002). Bronchial 
apomucins have been documented to share similarities with intestinal apomucins; their 
tandem repeats are rich in threonine and proline residues (Gerard et al., 1990, Perini et 
at., 1989). Similar apomucins are also common to glycoforms of mucins. MUC5B, a 
dominant gel forming mucin in the respiratory tract, has been documented to have a high 
and low charge glycoform (Wickstrom et aI., 1998). 
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1.5 Mucin genes 
The mucin gene family consists of 20 members numbered according to their description 
(MUCl, MUC2, MUC3A, MUC3B, MUC4, MUC5AC, MUC5B, MUC6-9, MUCl1 , 
MUC12, MUC13, MUC15-l9, and MUC20 (Rose and Voynow, 2006). Of the 20 
members, MUCl, MUC2, MUC4, MUC5AC, MUC5B, MUC7, MUC8, MUCl1, 
MUC13, MUC15, MUC 19 and MUC20 have been detected at the mRNA level in the 
lower airways of healthy individuals (Rose and Voynow, 2006). MUCl, MUC2, MUC4, 
MUC5AC, MUC8 and MUC13 are expressed in the surface epithelium; the goblet cells 
produce mainly MUC5AC. MUCl, MUC2 and MUC8 are also expressed by the 
submucosal glands together with MUC7, MUC19 and the dominantly expressed MUC5B 
(Davies et ai., 2002, Rose and Voynow, 2006). 
Recombinant DNA technology has categorised the 20 mucins into 3 groups depending on 
their structural similarities (Rose and Voynow, 2006). The secreted or gel forming 
mucins are MUC2, MUC5AC, MUC5B, MUC6 (Davies et al., 2002) and the recently 
discovered MUC19 (Rose and Voynow, 2006). MUC7 is classified as a soluble mucin 
which is secreted but not gel forming mucin (Davies et ai., 2002) and MUCl, MUC3A, 
MUC3B, MUC4 MUC12, MUC13, MUCI5-17, MUC18 and MUC20 are the membrane 
bound mucins (Moniaux et ai., 2001, Rose and Voynow, 2006). MUC 11 has also 
recently been associated with the membrane bound mucins (Davies et al., 2002). 
According to Davies et al (2002), MUC8 is a membrane bound mucin. Rose and 
Voynow (2006) describe MUC8 as a secreted mucin that lacks the von Willebrand factor. 
1.5.1 Soluble mucins 
MUC7 is a secreted, non-cysteine rich mucin incapable of gel formation due to its simple 
structure (Voynow, 2002) (Figure 1.2). Its cDNA encodes for a 39kKDa protein 
comprising of 377 amino acids. It has about 6 or 7 tandem repeats each of which have 23 
residues and appears to have just two cysteine residues both of which are found near the 
N-terminus of the molecule. MUC7 is a potent antimicrobial agent in the oral cavity. It 
has been reported to interact with a variety of oral micro organisms such as Pseudomonas 
aeruginosa, and is believed to be involved in the binding and inhibition of HIV-1 thereby 
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preventing oral transfer of the virus. These properties have been associated with the 
activity of the two cysteine residues. Furthermore, MUC7 has a histatin-like domain 
associated with anti-candidal properties (Moniaux et aI., 2001). 
1.5.2 Membrane bound mucins 
Membrane bound mucins are localized within the cell membrane (Rose and Voynow, 
2006). The membrane bound mucins or cell associated mucins are composed of two 
domains: hydrophobic or transmembrane domains, which span the length of cell 
membranes, and mucin or cytoplasmic domains (Figure 1.2). MUCI (Figure 1.2) was the 
first member of the group hence the most well defined membrane bound mucin (Davies 
et al., 2002). MUC3, MUC4 (Figure 1.2) and MUC12 lie in a cluster on chromosome 
7q22. The membrane bound mucins are further subdivided into four groups namely the 
membrane anchored form, the soluble form, the secreted form and those that lack the 
characteristic tandem repeat (Moniaux et al., 2001). The soluble form is a result of 
proteolytic cleavage of the membrane bound form. The secreted form and the form 
lacking the tandem repeat are similar in that both have alternative splicing variants. 
MUC3 and MUC4 are known to exist as splice variants which lack the transmembrane 
domains and hence give rise to soluble forms of the two mucins (Davies et al., 2002). 
In general MUC1, MUC3, MUC4, MUC8, MUCII and MUC12 are expressed at the 
epithelial surface by virtue of their transmembrane domains. MUC 1 and MUC4 appear 
to extend further into the luminal surface in comparison to the other mucins; and MUC3 
and MUC4 contain epithelial growth factor (EGF)-like domains in the extracellular 
portion ofthe transmembrane subunit (Davies et al., 2002). 
1.5.3 Secreted mucins 
Secretory mucins are housed within granules or vesicles and are released at the apical 
surface of the cell when stimulated by secretagogues (Rose and Voynow, 2006). MUC2, 
MUCSAC, MUCSB (Figure 1.2) MUC6 and MUC19 are the secreted mucins or gel 
forming mucins. Their genes are located on chromosome IIp IS.S and appear to code for 
similar amino acid sequences which result in (Moniaux et al., 2001) large oligomeric 
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configurations (Davies et al., 2002). Their oligomeric structure is vital for gel formation 
(Voynow, 2002). Gel forming mucins are susceptible to solubilisation using chaotropic 
agents such as guanidinium chloride (GuHCl). Colonic MUC2 and salivary MUC5B are 
the exceptions as they strongly resist solubilisation in GuHCl. Thiol reduction of MUC2 
produces mucin monomers and a range ofoligomers suggesting that the MUC2 apomucin 
is held together by disulphide bonds and a yet unknown "reduction resistant-linkage" 
(Davies et ai., 2002). The secreted mucins share a sequence homology with the von 
Willebrand factor (vWF); they have cysteine rich domains at the amino and carboxyl 
termini which serve as sites for oligomerisation (Figure 1.2) (Voynow, 2002). They also 
have cysteine rich sequences interspersed within the apomucin (Figure 1.2) (Davies et ai., 
2002). They are known to complex with other mucins and proteins via thiol, ionic and 
hydrophobic interactions (Rose et ai., 2001). 
MUC5AC and MUC5B exist in a range of size (2-30x106 kDa) in the respiratory and 
cervical tracts. Disulphide cleavage of the two MUCs yields mucin subunits (2-3 x106 
kDa) indicative of mucin monomers, and proteolytic digestion of reduced subunits yields 
protease resistant mucin domains (3-5 xl05 kDa). According to electron microscopy 
intact MUC5AC mucins are long, linear threads composed of 18 monomers. MUC5B 
appears as a mass of entangled filament like structures (Davies et ai., 2002). 
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Figure 1.2 Schematically illustrates the majors domains within the soluble, 
membrane bound and secreted mucins. A. Membrane tethered mucins represented by 
MUCI and MUC4, B. Secreted, noncysteine rich mucin represented by MUC7 and C. Secreted 
cysteine rich mucins represented by MUC2, MUC5AC and MUC5B . PTS, Proline Threonine 
Serine; SEA, Extracellular domain associated with O-glycosylation, EGF, Epidermal growth 
factor like domain, vWF, Von Willebrand factor; AMOP, adhesion associated extracellular 
domain. (Rose and voynow, 2006) 
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1.6 Characterisation of mucins 
Mucin characterisation allows one to differentiate between varying mucin types and to 
determine the presence of specific and dominant mucins in varying secretions. It further 
provides insight into the presence of novel mucins and mucin glycoforms. Physical 
methods were employed in characterisation studies but had proven to be challenging due 
to the large molecular weight of glycoproteins, their polydispersity and increased 
viscosity in solution. The tenacious nature of mucins added to this challenge via 
intermolecular forces which enabled mucins to readily form gels at moderate 
concentrations and to strongly adhere to supporting media (Holden et ai., 1971). 
Methods such as sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS­
PAGE) appeared promising during initial mucin studies but were soon found to have 
some limitations. SDS-PAGE gels are based on the principle that proteins are separated 
depending on their size. This principle falls short when attempting to characterise large 
hydrodynamic mucins. The polyacrylamide gel is incapable of separating high molecular 
weight mucins such as MUC5AC, MUC5B and MUC2, the movement of which through 
a gel becomes retarded resulting in the mucins remaining in the stacking gel or at the 
beginning of the running gel. SDS-PAGE gels were first modified into SDS-agarose gels 
(Tytgat et ai., 1995). Holden et ai (197 1) had studied the effect of physical degradation 
and disulphide bond cleavage on canine tracheal mucins by incorporating 1-2% agarose 
into a 7.5% acrylamide gel system. The high porosity of the agarose facilitated entry of 
the large molecular weight mucins. Mucin studies such as those by Carlstedt, Thornton 
and Sheehan, throughout literature, illustrates the advantage in using agarose gels without 
acrylamide during mucin characterisation (Sheehan et ai., 1996, Thornton et ai., 1996). 
SDS-PAGE gels are used to determine the purity of CsCI purified mucins; the gel should 
appear protein free with purified mucins remaining at the origin of the running gel. 
1.7 Respiratory mucins 
Characterisation of a normal human adu1t lung revealed the presence of 12 MUC genes 
identified in terms of their mRNA. These MUCs are MUCl, MUC2, MUC4, MUC5AC, 
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MUC5B, MUC7, MUC8, MUC11 , MUC13, MUC15, MUC 19 and MUC20. Their 
expression is hypothesized to vary dur ing development (Lamblin et at., 2001). In the 
normal adult lung they are expressed between the upper and lower respiratory tract and 
are hence specific to certain cell types. MUC1, MUC2 and MUC4 are found in all 
superficial airway epithelial cells (Voynow, 2002). Mucin gene regulation studies were 
initially carried on the MUC2 cDNA and promoter as they were present before the 
MUC5AC and the MUC5B genes were cloned and characterized (Rose and Voynow, 
2006). MUC2 is generally expressed at low levels , specifically during bacterial invasion 
(Kim et at., 2003). Pseudomonas aeruginosa, a known pathogen of cystic fibrosis, 
activates NFKB in the MUC2 promoter hence inducing MUC2 expression (Lamblin et at., 
2001, Leikauf et at., 2002) which is followed by the up regulation of MUC5AC (Lamblin 
et at., 2001). As previously mentioned MUC7 is expressed in serous cells of the 
submucosal gland, MUC5AC is expressed in the goblet cells and MUC5B in the 
submucosal glands. Antibody detection has identified MUC5AC and MUC5B as the 
dominant glycoproteins in a healthy respiratory tract (Voynow, 2002, Lamblin et at., 
2001). Irritated or diseased airways have also illustrated the presence of MUC5AC, 
MUC5B and at times MUC2 in their secretions, with either MUC5AC or MUC5B 
appearing more prominent (Davies et at., 2002). 
1.8 Mucus and mudns in Respiratory diseases 
Mucus hypersecretion is strongly associated with respiratory diseases such as chronic 
bronchitis, bronchiectasis, asthma and cystic fibrosis (Buisine et at., 1999). It has also 
proven to be an irritation to the sinuses. It impedes the action of the mucociliary blanket 
and leads to a reduction in airflow. This in turn results in stagnant mucus which behaves 
as an ideal medium for bacterial colonisation and viral infection (Ho et at., 1993, Adler 
and Li, 2001). Mucus hypersecretion during chronic airway diseases is promoted by 
metaplasia and hyperplasia of mucus secreting cells (Figure 1.3) (Vilar et at ., 2003). 
Literature has underlined the central role of mucus in the pathogenesis of severe airway 
obstruction and asphyxiation in fatal asthma (Hovenberg et at., 1996). Acute 
degranulation of hyperplastic goblet cells occurs during mild and moderate asthma 
exacerbations (Rose, 1992) and the numbers of mucus secreting cells increase in chronic 
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bronchitis after the inhalation of tobacco smoke (Figure 1.3) (Jeena et ai., 2002). 
The large gel forming mucins MUC5AC and MUC5B are responsible for the rheological 
(flow) properties of respiratory mucus (Fontenot et ai., 1995, Bradshaw et ai., 2002, 
Fontenot et ai., 1996) and knowledge of the types of mucin, their cellular origin, 
synthesis, secretion and eventual fate in the respiratory tract in disease may therefore 
provide insights into aspects of the pathogenesis of these conditions. Airway irritation, 
carcinogenesis, chronic bronchitis and cystic fibrosis, do not appear to be associated with 
production of novel glycoprotein moieties (Jeena et ai., 2002). However, in asthma 
(Fontenot et ai., 1996) and chronic bronchitis (Jeffrey and Li., 1997), the predominant 
respiratory mucin MUC5B can exist as two glycoforms (Fontenot et ai., 1996, Jeffrey 
and Li, 1997), with different densities of charge and different lengths of glycosylated 
domains (Fontenot et ai., 1996). The existence of two glycoforms of the MUC5B gene 
product raises questions as to whether they are both present in the normal situation, 
whether their level changes between normal and diseased conditions, and if they are the 
product of the same or different cells. MUC2 has been detected in the respiratory tract 
during inflammation associated with asthma (Fontenot et ai., 1996). It is hypothesized 
that the presence of MUC2 causes changes in the physicochemical properties of the 
various gels on the respiratory epithelium, which could impact on treatment in the future. 
Longer MUC2 alleles are also present in atopic non-asthmatics, in comparison to 
asthmatics (Fontenot et aI., 1996), suggesting that specific glycoforms could have 
protective properties against certain diseases. 
Mucus overproduction is a major source of morbidity and mortality to airway diseases 
and leads to a severe loss of pulmonary function, yet the role of mucus and mucus 
secreting cells in the respiratory tract is poorly understood. In fact determining the levels 
and the quantity of mucus in vivo is problematic. Various obstacles are encountered 
during sample collection from volunteers and diseased patients. This leads to the use of 
post mortem samples which in tum present wih problems dues to proteolytic degradation. 
It is likely that mucins are the key to understanding airway pathologies yet the knowledge 
surrounding these glycoproteins is also limited. 
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Figure 1.3 Illustrates the impact of external and internal irritants to the airways. 
When healthy human airway epithelia (middle) are exposed to pathogens or immune mediators 
the result is either chronic or acute mucin hypersecretion. Chronic mucin overproduction leads to 
airway diseases such as asthma were hyperplasia and metaplasia reflect a division in goblet cells, 
differentiation of progenitor cells and/or transdifferentiation of airway epithelial cells (bottom 
left). During an acute attack (bottom right) external pathogens or mediators activate mucin 
secretion from goblet cells and/or submucosal glands. Certain mediators also upregulate MUC 
gene transcription hence maintaining the hypersecretion and overproduction of mucin. An acute 
attack can be controlled by anti-inflammatory mediators and mechanisms resulting in a the 
airways reverting to a normal healthy state. (Rose and Voynow, 2006) 
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1.9 Tuberculosis (TB) 
Mycobacterium 	 is a highly airbourne responsible 
. The bacilli are contained and hence spread in droplets between individuals in close 
contact with each or within closed (Munch et al., 2003). Once inhaled 
VIJ"v,c>. at 51lm (Middleton et they travel the respiratory 
tract to its primary of infection, The are 
invading other parts the body by _ •••_ ....,l") from the via lymphatic or 
blood system to pleura, lymphatics, genito-urinary system, minenges, 
peritoneum or skin 2004). 
1.9.1 The impact 
the century what is now as pulmonary 
was identified as 	 source behind 1 in 5 the London Bills Mortality. It was 
19threnamed the White of Europe, a name that stayed up until the century. 
this period became pandemic resulting in 7 million deaths per year; a 
rate that with time 2004). TB has the worlds leading 
infectious disease discovery to on unrivalled 
mortality rate at 3 million UvU""" annually, estimating 5 per minute. It 
is approximated that 10 million people are infected per year with highest incidence 
rate (290 cases 11 00000 indi iduals) lying 9 of 10 African (Walzl, 2004) and 
more than half the cases lying in five South Asian countries (Uplekar et al., 2001). 
World (WHO) 2003 that if is not effectively 
controlled one billion will be newly by 2020 due to influence 
HIV pandemic, movement of populations, demographics drug 
(Kanduma et al., Africa boasts annual growth rate of TB (6%) (Walzl, 
2004). 
appears to women and In 2000, children 1.3 
of estimated million new TB cases globally. Children accounted for 450 000 
the 3 million attributed to TB in that year (Jeena et 2002, Madhi et aI., 
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2002). Studies related to children hospitalized with community acquired pneumonia in 
an urban area of the Western Cape in South Africa reported that TB occurred in 
approximately 8% of children, irrespective of their HIV status (Zar et al., 2000). In 1998, 
mortality related to TB was lead by women. Approximately three-quarters of a million 
women died of TB and about 3 million women contracted the disease (Uplekar et al., 
2001). 
Despite efforts to control TB, it appears to be on a rampage, especially HIV related TB. 
Between 1993 and 1998 the TB cases in South Africa increased from 249 to 326 cases 
per 100 000 individuals. This illustrated a 31 % increase (Munch et al., 2003). The 
Western Cape Province in particular hosts the greatest number of TB cases in South 
Africa. A study carried out in the Cape Town suburbs of Ravensmead and Uitsig 
associated TB with socioeconomic classes prone to unemployment, overcrowding and 
various poverty related factors (Munch et al., 2003). The lack of medical resources and 
the prevalence of HIV-AIDS, amongst other factors, have resulted in the poor 
management of TB especially amongst those of lower socio-economic status (Bradshaw 
et al., 2002), who constitute the majority of the population . 
1.9.2 TB and respiratory mucosal surfaces 
The understanding of the pathogenicity of Mycobacterium tuberculosis is limited but 
studies conducted by Middleton et al (2002) report that mycobacteria have been 
illustrated to penetrate the respiratory mucosa. They are known to adhere to M-cells, 
which are epithelial cells involved in transporting particles across the mucosal barrier. 
M-cells are found above lymphoid tissue; this is of significance as it is suspected that 
bronchial-associated lymphoid tissue cou ld be the primary entry site for Mycobacterium 
tuberculosis into the airways. The mycobacteria are also known to adhere to fibronectin 
and in doing so are further suspected to colonise mucosal surfaces. The role of 
fibronectin in bacterial colonisation was first illustrated when M. Bovis BCG was found 
to adhere only to damaged areas (Figure l.4b) of the bladder epithelium. M. Bovis and 
M. avium have been shown to complex with a fibronectin by means of the fibronectin 
attachment protein (FAP). Similarly, Mycobacterium tuberculosis is suspected of 
18 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
binding to potential 85B component antigen 85 
(Middleton et ai., 2002). 
an organ culture model Middleton et (2002, 2003) demonstrated that 
Mycobacterium tuberculosis adheres to "a particular fonn of mucus and occasionally to 
unciliated extruded and between with separated tight 
junctions" (Figure l.4a). They also attachment mycobacteria to 
cells could in endobronchial observed in ,u"",,,,,,,",u states and in an 
animal model. 
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1.4a 
1.4 
Figure 1.4 Scanning electron micrographs of Mycobacterium tuberculosis in 
respiratory mucosa. l.4a illustrates the binding of the mycobacterium to healthy unciliated 
mucosa and l.4b illustrates the adherence of the mycobacterium to damaged mucosa in the 
extracellular matrix. (Middleton et aI. , 2002) 
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1.9.3 TB and Mucins 
Despite their prevalence and the fact that diseases such as HIV and TB are considered to 
be one of the major causes of death in South Africa (Kirkbride et al., 2002), the role of 
mucus and mucins in the pathogenesis of diseases such as TB has not been investigated. 
It is known that recurrent hypersecretion of mucus with increased amounts of mucin is 
characteristic of diseases such as TB (Bobek et ai., 1993). Furthermore it is hypothesized 
that the mechanism behind the development of endobronchial TB involves the 
colonisation of the respiratory mucosa by Mycobacterium tuberculosis (Middleton et al., 
2002, Middleton et ai., 2003) but knowledge concerning the type and amounts of specific 
mucins related to TB is minimal. This is the first known study concerning the role of 
mucus and mucins in TB. It is proposed that the findings of this study would contribute 
further to the understanding of the pathogenesis, treatment and management of TB as TB 
patients are known to produce vast quantities of mucus (Epstein et al., 1987), which in 
general is known to aggravate a variety of respiratory diseases. 
1.10 The biochemical objectives of this study 
The biochemical aspect of this study aimed to determine the type of mucin/s secreted in 
children and adults with TB and to a) compare these with normal non-TB secretions, b) to 
determine the dominant mucins in children and adults with TB and c) to determine the 
roles of these mucins. The hypothesis is that besides the up-regulation of commonly 
expressed respiratory MUC5AC and MUC5B mucins in TB, a change in chemical 
composition and the expression of different glycoforms of these mucins are associated 
with disease, together with the possibility of the expression of other mucin(s), which 
would impact on the pathogenesis of TB. 
1.10.1 The biochemical techniques 
Mucus samples from adults and children with TB, along with controls were purified by 
caesium chloride (CsCI) density gradient centrifugation, and their purity determined by 
SDS-PAGE. Purified mucin was thereafter subjected to amino acid analysis to determine 
if the chemical composition of the mucins differed between the TB positive state and 
controls. Mucins were also subjected to agarose gel electrophoresis. MUC5AC, 
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MUC5B and MUC2 antibody detection was essential to the study as it served to illustrate 
the presence of the dominant mucin types, the presence of mucin glycofonns and novel 
mucin types; in doing so it was hypothesized that differences would be found in the TB 
and control groups. 
1.11 Molecular study of TB and mucins 

A brief molecular study was also conducted on children and adults with TB. 

1.11.1 Respiratory mucin genes 

The MUC5AC, MUC5B and MUC2 genes are gel fonning mucins found on chromosome 

Ilp15.5. MUC5AC and MUC5B gene products dominate the goblet cells and 

submucosal glands of the respiratory tract, respectively. The MUC2 gene products have 

also been described in the airways specifically during bacterial invasion. Thecentral 

domains of MUC5AC and MUC2 contain tandem repeats rich in serine, threonine, 

glycine and alanine. They are flanked at either end by unique cysteine rich domains and 

appear similar to each other in amino acid sequence. These sequences are also similar to 

the human pro-von Willebrand factor (Desseyn et al., 1998). 

The MUC5B gene is comprised of 48 exons and 47 introns. It has an unusually large 
central exon (exon 30, 10713 bp) which houses a serine and threonine rich tandem repeat. 
MUC5B presents with a direct perfect repeat of 59 bp in intron 36 (previously known as 
intron G), which is identified by the following sequence: cctgtgcggt gagtgggggc 
ggccccgggc cccccagacc cctcggcctc tctgagtgt (Desseyn et al., 1999). 
MUC5B and MUC5AC appear similar at the peptide leveL According to Desseyn et ai., 
(1999), MUC5AC, MUC5B and MUC2 may have evolved from the same ancestral line; 
this is supported by the fact that are classified as a subclass of mucins comprised of 
cysteine sub domains that occur several times between their heavily glycosylated regions 
(Figure1.2) (Desseyn et ai., 1998). The majority of mucin genes appear to have high 
levels of genetically detennined polymorphisms (Vinall et ai., 2000). MUC5B in 
• 
•I 
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particular presented with a polymorphism within intron 36 which is speculated to playa 
role in gene regulation (Desseyn et al., 1999). 
1.11.2 Mucin polymorphisms 
The polymorphisms of the apomucin and the structural variation of the oligosaccharides 
has allowed for vast inter-individual differences in the structure of mucins. These 
differences have possibly allowed species to adapt to changing environments; this is 
observed in microbes and viruses that alter their properties through mutations. 
Polymorphisms of mucins may be advantageous to a population at large but are capable 
ofmaking certain individuals more susceptible to bacterial colonisation or antigen attack 
(Davies et al., 2002). 
1.11.3 Mucin genes and Respiratory diseases 
Mucin genes are highly polymorphic due to the presence of long stretches of variable 
number of tandem repeats (VNTRs) that are heavily glycosylated (Rose and Voynow, 
2006). VNTRs are a result of the instability of the number ofrepetitiorts that occur from 
generation to generation (Moniaux et al., 2001). They take up a large part of the coding 
region and are very similar but not identical to each other. Lengthwise, they range 
between 24 nucleotides in MUC5AC to 507 nuc1eotides in MUC6 (Vinall et al., 2000). 
In a number of human diseases, aberrant O-glycosylation is associated with variations in 
the properties of the membrane-associated and secreted mucins (Reid et al., 1999). 
Several studies reported an association between disease, for example in asthma, and the 
length of the VNTR region (Vinall et al., 2000, Kirkbride et al., 2001, Rose and Voynow, 
2006). This association was also made with polymorphisms at the level of a single 
nucleotide as in ulcerative colitis (Kyo et al., 2001), and in allelic variation in subjects of 
different ancestry (Kirkbride et al., 2001). The over-expression, followed by hyper­
secretion, of mucins has been established secondary to inflammatory diseases (Vinall et 
al., 2000, Voynow 2002). MUCl, MUC2, MUC4, MUC5B and MUC5AC have each 
been expressed in inflamed and noninflamed tissue at the mRNA and protein levels. 
With the exception ofMUC5B they have also illustrated allelic length variation (Desseyn 
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et ai., 1999, Vinall et ai., 2000). This length variation is observed in "longer" MUC2 
alleles suspected of protecting predisposed individuals from the development of asthma. 
In contrast MUC5B is hypothesized to have rare variant length alleles present during a 
diseased state such as severe asthma. If so, this would explain the presence of large 
amounts of MUC5B that were found in an individual who died from status asthmaticus 
(Vinall et ai., 2000). 
Investigations involving obstructive lung diseases generally focus on the expression of 
MUC5AC and MUC5B, as their mRNA is well expressed in normal airways and their 
gene products have been identified in increased concentrations in lung mucus of 
asthmatic patients (Rose et aI., 2001, Voynow 2002). In chronic obstructive pulmonary 
. disorder (COPD) patients, MUC5AC is believed to be controlled by inflammatory 
mediators, such as cytokines. MUC5AC and MUC5B gene expression in normal and 
diseased airways is generally greater than that of MUC2 or MUCI (Voynow et ai., 1998, 
Voynow,2002). MUC2 produces a diffuse, weak signal in normal respiratory epithelium 
which increases in inflamed airways (Leikauf et ai., 2002). Various studies support the 
hypothesis that MUC2 is more actively involved in the pathogenesis of inflammatory 
airway diseases such as cystic fibrosis; during which the MUC2 gene is transcriptionally 
activated by Pseudomonas aeruginosa (Buisine et aI., 1999). MUC2 mRNA expression 
was shown to be further elevated in rat airways damaged by S02_, endotoxins and viruses 
(Jany et ai., 1991, An et aI., 1994). In general, the overexpression of MUC5AC, MUC5B 
and MUC2 has been associated with asthma, cystic fibrosis and chronic bronchitis; 
diseases strongly associated with mucus obstruction and goblet cell hyperplasia and 
metaplasia. Each of these pathologies has via in vitro studies been linked to mucin 
expression (Voynow, 2002). 
1.11.4 The genetic susceptibility to TB 
TB has reached epidemic proportions and is suspected to be related to a genetic 
susceptibility within certain popUlations (Hoal et ai., 2004). The condition has been 
linked to various polymorphisms such as SLC11A1 (previously known as NRAMP 1) 
(Hoal et aI., 2004). SLCllA1, according to Hoal et ai (2004) is associated with 
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protection against TB in most of the populations studied. Investigations involving 
restriction fragment length polymorphisms (RFLPs) have also made strong ties between 
ones lifestyle and a susceptibility to TB. This lifestyle is associated with prisons, bars, 
homeless shelters, and in general poverty (Munch et ai., 2003, Hoal et ai., 2004). A 
strong association was also made between the incidence of TB and unemployment and 
overcrowding (Munch et al., 2003). 
Furthermore it appears that the ethnicity of a population is involved in regulating genes 
that are associated with TB susceptibility. Generally within the world, the Asian and 
African populations have presented with high incidences of TB in comparison to the 
Caucasian population, which is usually found to have a low incidence of TB. Within 
South Africa terms such as Black, White, Coloured (mixed race) and Indian are used to 
identify the different races. The Coloured population in the Western Cape has presented 
with the highest incidence of TB in South Africa. Their gene pool has been influenced 
by Khoisan, Malaysian, Black and White populations and has therefore been the focus of 
various molecular studies regarding TB (Hoal et al., 2004). South Africa, particularly the 
Western Cape, has presented with an ideal environment for various TB related studies. 
The demographic profile and differences in socio-economic conditions amongst various 
population groups provides the opportunity to study the impact of polymorphisms and TB 
susceptibility. The role of respiratory mucin gene polymorphisms has previously not 
been investigated in TB. An investigation into this association is of significance as 
respiratory mucin gene polymorphisms could make certain individuals more susceptible 
to TB than others. 
1.11.5 The objectives of the molecular study 
The molecular aspect was a pilot study that focused on genetic polymorphisms in mucin 
genes and their associated susceptibility to TB. The objectives included a) determining if 
the genetic polymorphisms for MUC2 and MUC5B reported in the literature were also 
present in the Western Cape population and b) and to gauge if a large scale investigation 
would be warranted. 
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CHAPTER TWO 
MATERIALS AND METHODS 
COLLECTION 

OF CRUDE 

SPUTUM AND 

SCRAPES 

Homogenis3tion 

3nd 

Centrifug3tion 

Reduction 3nd Alkyliltion of 
crude samples 
MolecularWestern Blotting of / 
CsCI Studycrude S3mples 
Purification 
/
Western Blotting of Amino Acid analysis 
purified samples 
• Figure 2.1 illustrates a flowchart of the methods carried out in the study. 
2.1 Materials 
Poly-L-Lysine, resorcinol, guanidinium chloride (GuHCI), agarose (TYPE V), urea and 
bovine albumin were obtained from Sigma Company St Louis U.S.A. Sodium chloride, 
dialysis tubing, Super Fuji Medical X-ray film HR-GB (18-24cm) were purchased from 
Kimix, SA. Ethylenediaminetetra-acetic acid disodium salt (Na2-EDTA), Tris••II 
 (Hydroxymethyl) aminomethane, ammonium persulfate, iodoacetamide (IAA), Folins 
• 
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Ciocalteu's phenol reagent acrylamide, NN'-methylenebisacrylamide (Bis), ammonium 
persulfate (AMPS), N-ethylmaleimide (NEM), sodium metabisulphate, sodium dodecyl 
sulphate (SDS). periodic acid and 2-mercaptoethanol were supplied by the British Drug 
House (BDH), Dorset, UK. ECL Western Blotting detection reagents were supplied by 
Amersham Biosciences. Nitrobind pure nitrocellulose (0.22!!) was supplied by Kimix, 
Cape. Sodium carbonate anhydrous, di-sodium hydrogen orthophosphate anhydrous and 
sodium dihydogen orthophosphate were from SAARCHEM (Merck). ULTRA­
CLEARTM centrifuge tubes (16x76mm) were supplied by Beckman International. Buccal 
swabs were purchased from Cliniscience. The Sepharose CL-2B column was supplied by 
Pharmacia Ltd, Buckinghamshire U.K. 
2.2 Collection of crude sputum samples and mucus scrapes 
Samples were obtained from 4 different groups: 
~ 
1. sputum from healthy adult volunteers (V) 
2. mucus scrapes from the tracheas of cadavers (PM) 
3. sputum from diseased adults (1) 
4. sputum from diseased HIV+ children (RX) 
Groups I and 2 were the control groups. The volunteers were "healthy" in that they 
declared themselves as such at the time of the study. Sputum samples were induced with 
0.9% sodium chloride for 15 minutes via a Nebysol nebuliser and collected on ice. 
Samples were obtained from post mortem cadavers 48-72 hours after death. Crude 
mucus scrapings were collected on ice by slitting the trachea longitudinally and scraping 
the epithelial surface with a metal spatula. 
The adults at risk for TB were drained from the area known as the Cape Flats which is 
occupied predominantly by the population known as the Cape Coloured, so called 
because of its ethnic mixture (mostly Khoisan, Caucasian, Xhosa· and Indonesian). 
Patients suspected of having tuberculosis were identified by medical staff of the intake 
wards at GJ. Jooste Hospital. Sputum was taken from these patients prior to any 
treatment. Patients rinsed their mouths with water before expectorating into a pre­
weighed jar containing 6M GuHCI, on ice. A nursing sister was called upon to assist if 
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and when a patient required assistance to mobilise sputum. A medical intern also assisted 
in seeking out patients and in the collection of samples. A clinical report was compiled 
on the method of TB diagnosis and the presence of extraneous complicating factors 
related to mucus production (Chapter 3, Clinical data). 
Children were intubated to obtain tracheal mucus at Red Cross Children's Hospital. All 
these children were HIV positive and diagnosis of TB was made as described above. 
Material for DNA analysis was taken by scraping the mucosal lining of the inner cheek 
with a buccal swab in groups 3 and 4. The samples obtained for the 4 groups were 
solubilised in 6M Guanidinium hydrochloride (GuHCI) made up in sodium phosphate 
buffer containing proteinase inhibitors, namely 10mM EDTA and 5mM NEM. Swabs 
and samples were stored at 4°C until further investigations. 
2.3 Solubilisation of samples 
The mucus scrapings from cadavers and sputum samples were homogenised with a 
Junkel and Kunkel Ultra-Turrax (40sec, 9500min-1, RT) to disaggregate the sputum and 
increase its solubility in GuHCl. After sonication the samples were centrifuged in a 
HITACHI, HIMAC centrifuge (60min, 3000rpm, 4°C) to remove insoluble debris (Allen, 
1977). The supernatant was removed and stored at -20°C. 
2.4 Purification of mucins 
Mucins were purified via the CsCI density gradient method. The samples were subjected 
to two 48hr spins at 40 OOOg, 4°C (Creeth and Denborough, 1970, Starkey et al., 1974). 
The density of the samples was adjusted to values between 1.39-1.4g/ml using GuHCI 
and CsCl. After centrifugation the samples were fractionated in a top down method into 
8 fractions. The fractions were dialysed to remove CsCI and a Lowry and PAS assay 
were carried out to determine the presence and level of protein and carbohydrate in each 
fraction. After the second spin the fractions that contained the purified mucin peaks 
(Starkey et al., 1974, Pearson et al., 1980) were pooled, dialysed against distilled water 
and freeze dried. 
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2.5 Reduction and alkylation 
The samples were reduced in 6M GuHCI andlOmM DTT for 5hrs at 37°C. DTT disrupts 
disulfide bonds in mucus and allows for a uniform dispersal of cells (Hargreave, 1999). 
The resulting sulfhydryl (-SH) groups wer.e then treated with 25mM IAA, overnight in 
the dark, to avoid the re-formation ofnon-specific disulphide bonds. 
2.6 Analytical procedures 
2.6.1 Lowry assay 
The Lowry assay was carried out according to the method of Lowry et al (1951). It 
makes use of the Folin-Ciocalteu reagent to either quantitatively or qualitatively 
determine the concentration of proteins. The quantitative assay requires the use of a 
standard curve. The assay is based on two vital steps whereby a) copper reacts in an 
alkaline solution and b) the Folin-Ciocalteu reagent is reduced. The advantages to the 
Lowry method include its sensitivity to detect low protein concentration (Oosta et ai., 
1977), which is greater than the biuret and ninhydrin reactions (Lowry et ai., 1951). It is 
also more sensitive than UV detection of proteins at 280nm. It falls short with respect to 
constancy as the colour varies depending on the protein and is not necessarily 
proportional to the concentration (Lowry et al., 1951). The standard was created via a 
doubling dilution using bovine serum albumin (BSA) as the standard protein. A solution 
containing alkaline and copper added to the samples. After 10mins diluted Folins reagent 
(200JlI) was added to the samples which were mixed and incubated at 25°C for 30mins. 
The absorbance of the samples was read at 70Onm. 
2.6.2 PAS assay 
The PAS assay was carried out to determine the presence and relative amount of mucin 
during CsCI purification. The principle involves the oxidation of vicinal hydroxyl groups 
by periodic acid and the coupling of a Schiff base (PAS) to identify glycoproteins 
(Mantle and Allen, 1978). Periodic acid oxidation results in the formation of two 
aldehyde groups which combine with the Schiff base to form a red solution. The PAS 
method is a reliable, simple and sensitive assay for the colorimetric detection of 
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carbohydrates. It has proven to be 20 times more sensitive than the orcinol assay, 10 
times more sensitive than measuring at A280 and 3 times more sensitive than the anthrone 
assay with respect to the detection of gastric glycoproteins. It is important to note that 
detergents containing formaldehyde are extremely Schiff sensitive or PAS positive and 
could interfere with the results. In this study distilled water (950).!1) and periodic acid 
solution (200).!1) were added to the sample (50).!1). This solution was incubated at 37°C in 
a water bath for an hour. Simultaneously Schiff's reagent was prepared and incubated at 
37°C in a water bath until the solution turned colourless. The decolourized Schiff's 
reagent (200).!1) was added to the samples. The samples were vortexed and left to stand at 
room temperature for 3 Omins. A graph of the absorbance of the mucins was read at 
555nm. 
2.7 Biochemical procedures 
2.7.1 Dialysis 
Dialysis was carried out during the purification procedure a) to remove GuHCI and CsCI 
as they interfere with the Lowry and PAS assay and b) to concentrate the purified mucin 
before freeze drying. It is common to small scale applications and is based on the 
principle of osmosis (Degerli et ai., 2001). One should note that detergents interfere with 
dialysis as they form high molecular weight micelles which also attempt to pass through 
the membrane pores (Stoscheck, 1990). Tubing was prepared for dialysis by boiling in 
distilled water with EDTA and sodium carbonate. The samples were dialysed at -20°C 
for 24hrs under constant stirring in a bucket of distilled water. 
2.7.2 Freeze drying 
After dialysis, purified samples were placed in plastic tubes with holes in the lids. They 
were then frozen by immersing the tubes in liquid nitrogen. The tubes were thereafter 
packed into vacuum flasks which were connected to a Christ ALPHA 1-5 freeze drier 
from Lasec Laboratory and Scientific equipment. The samples were dried at -80°C for 
approximately 24hrs. The lyophilised mucin samples were stored at -20°C until further 
investigations. 
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2.7.3 Western blotting 
Reduced and alkylated mucin subunits were separated by gel electrophoresis in 0.7% 
(w/v) agarose gels in 40mM Tris/acetate/lmM EDTA (Ix TAE), pH 8.0, containing 0.1 % 
(w/v) SDS. Loading buffer containing Ix TAE I 50% glyceroV bromophenol blue was 
added to the samples which were applied to the gel in volume equivalents. After 
electrophoresis, proteins were transferred to a nitrocellulose membrane by vacuum 
blotting in 0.6M sodium chioride/60mM sodium citrate (transfer buffer) with a Pharmacia 
VacuGene XKL apparatus at a suction pressure varying between 50-60mbar. Membranes 
were then probed with polyclonal anti-mucin antibodies (lh or overnight), provided by 
Dr Sara Kirkham, Manchester. LUM5-1 is a rabbit anti-serum raised against a synthetic 
peptide RNQDQGPKFMC (Hovenberg et al., 1996) corresponding to MUC5AC, 
LUM5B-2 recognises the epitope RNREQUGKFKMC (Wickstrom et al., 1998) in the 
NH2 terminus of the MUC5B apomucin, and LUM2-3 identifies the MUC2 epitope 
NGLQPVRVEDPDGC (Herrmann et al., 1999) situated in the non-tandem repeat region 
of the C-terminus (Aksoy et al., 1999). LUM5-1 and LUM2-3 recognise the fully 
glycosylated forms of MUC5AC and MUC2 respectively (Davies et al., 1999) 
Immunoreactivity was detected by development with an Enhanced Chemiluminescence 
System (ECL) (Amersham, UK) and the films were processed in a standard x-ray 
developer with an exposure time of five minutes. Reactivity with all three antibodies was 
tested for the four groups. 
2.7.4 SDS-PAGE 
A 10 % SDS-PAGE was setup according too Laemmli (1970), to evaluate the purity of 
samples after CsCI purification. The samples were dialysed in distilled water to remove 
the CsCI and GuHCl. They were thereafter reduced in reducing sample application 
buffer containing 2-mercaptoethanol. The gel was run at 20 amps until the bromophenol 
blue dye reached the bottom of the gel. Once complete the gel was stained with 0.2% 
Coomassie blue in 50% ethanol and 10% acetic acid to determine the presence of protein 
bands. The gels were thereafter de stained in 25% ethanol and 10% acetic acid to clear 
the background of the gel and to clearly view the protein bands. 
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2.8 Amino acid analysis 
The amino acid content of purified freeze dried mucins were analysed using a high 
pressure liquid chromatography (HPLC) system. The analysis procedure was similar to 
that of Klapper (1982). Norleucine was used as a standard for the calibration of peaks. 
The samples were vacuum dried and placed in a hydrolysis vessel containing constant 
boiling HCl and 1% (v/v) phenol. The vessels was purged with nitrogen gas and sealed 
under vacuum. The samples were then hydrolysed in the gas phase at 110°C for 24hrs. 
Following hydrolysis, the vials were cooled and vacuum dried to remove the residual 
HCl. The dried samples were redissolved in citrate buffer pH 2.2 and injected into a 
HPLC column from Waters Associates, Medford, MA., packed with a cation exchange 
resin (sulfonated polystyrene crosslinked with divinylbenzene) and eluted with a series of 
buffers ranging from a low (0.25M trisodium citrate, pH 3.05) to high (0.25M sodium 
nitrate, pH 9.5) pH. Detection was carried out using post column derivatization with 0­
phthalaldehyde (OP A), a fluorescent reagent that reacts with all the amino acids except 
proline. Proline analysis was carried out separately and followed the same procedure 
with the exception of the use of OPA. 1 % sodium hypochlorite was used to detect 
proline as OPA is unable to interact with its ring structure. The relative ratios of the 
individual amino acids for each sample was determined and compared to each other. 
2.9 Molecular Study 
2.9.1 DNA extraction 
DNA was extracted from buccal swabs using the QIAmp DNA Mini kit (Qiagen, 
Germany). The Buccal Swab Spin protocol was performed as described in the 
manufacturer's manual. The swabs were washed in lxPhosphate buffered saline (PBS) 
to get cells into solution. The cells were lysed with proteinase K (40mAU/mg protein) 
and lysis buffer at 56°C. Buffering conditions were optimised to facilitate binding of 
DNA to the silica gel membrane whereas protein and other contaminants were allowed to 
pass through. Ethanol was added to the· solution which was mixed and transferred 
directly onto the filter of the spin column. After a series of washes using buffers 
... 
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designed to remove contaminants buffers, A WI and A W2, purified DNA was eluted by 
centrifugation in 100).1.1 of sterile distilled water. DNA was stored -20°C until further use. 
2.9.2 Polymerase Chain Reaction (PCR) primers 
Exons containing known variants for MUC2 and MUC5B were amplified using standard 
PCR techniques Primers used for amplification of the intronic MUC5B polymorphism 
are the same as those described by Vinall et al (2000). The primers were complementary 
to the variable number of tandem repeat (VNTR) region (Table 2.1). 
Table 2.1 Primers used for MUC2 and MUC5B PCR. 
I Gene Sense Primer Antisense Primer 
MUC2 5'-CTGAGCAACCTCGGCCTT -3' 5'-ATCGTCCAACCAGTCCAGC-3' 
MUC5B 5'AGTGTGCAGTGACTGGCGAG-3' 5'-CTAGAGTTGCAGGTGGCAGG-3' 
2.9.3 Polymerase Chain Reaction (PCR) 
PCR of the MUC5B and MUC2 alleles were carried out on purified DNA. The DNA 
was amplified in a PCR Sprint (Hybaid, UK) machine. Each MUC5B PCR contained a 
final concentration of (50 mM KC1, lOmM Tris-HC1, pH 9, 1.5 mM MgCh, 0.01% 
Triton-X), 0.25).1.M of deoxynucleotide triphosphates (dNTP's), lOpmol of Sense and 
Antisense primers, 7.5% glycerol, 3-5).1.1 of purified DNA, 1 unit ofD-aza for GTP, 1 unit 
Taq polymerase (SequiTherm, Hoffman-La Roche) with purified water making a final 
volume of 20).1.1. The cycling conditions were as follows: denaturation for 3mins at 95°C; 
30 cycles consisting of 30sec denaturation at 95°C, 30sec annealing at 60°C and a 45sec 
extension at noc and a final extension of 7mins at noc. Loading buffer was added to 
the PCR products and the molecular weight marker (MWM, Superladder-Low 100 
Ladder with ReddyRunTM from ABgene, UK) which were resolved by electrophoresis 
through a 2% agarose gel using the BIO-RAD MINI-SUB® GT. The amplified 
VNTR region of intron 36 of MUC5B was visualized with ethidium bromide under 
ultraviolet light. Two samples were used as controls during electrophoresis of the 
MUC5B PCR products. These samples were included in all gels to control for variations 
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across gels that occur due to variant running conditions (Vinall et al., 2000). To ensure 
correct sizing of alleles 0.25ug of the 1kb MWM was run on either side of the gel. 
PCR of the MUC2 alleles followed a similar procedure to that of the MUC5B PCR 
except for minor changes. The PCR cocktail for MUC2 excluded glycerol, MgC}z and 7­
deaza GTP, and the cycling conditions required annealing at 61°C and not 60°C. 
2.9.4 Restriction enzyme digestion of MUC2 
The MUC2 PCR products were digested with the restriction endonuclease, Pvull. The 
PCR product was treated with Pvull in a final volume of 25!!1 at 37°C for 2-4 hrs. 
Loading buffer was added to the digestion products and the MWM which were resolved 
by electrophoresis through a 2% agarose gel and thereafter visualized with ethidium 
bromide under ultraviolet light. 
2.9.5 Sequencing of MUC5B 
2.9.5.1 Gel extraction 
The MUC5B PCR products were electrophoresed on a 2% agarose geL Fragment sizes 
were approximated by comparison with the band sizes of the MWM. Whilst under iN 
light specific alleles selected for sequencing were excised from the gel using a scalpel 
and needle. The DNA was purified using the QIAquick® Spin gel extraction kit (Qiagen, 
Germany). The Qiaquick gel extraction protocol was carried out according to the 
manufacturer's manual. The gel slice was solubilized in a buffer containing (250ml 
Solubilization and Binding buffer, with a pH indicator) at 50°C to release the DNA. The 
addition of Isopropanol and a series of centrifugations facilitated the adsorption of the 
DNA to the membrane traces of agarose and other contaminants that could interfere with 
the sequencing procedure. The purified DNA was eluted by centrifugation in 30!!1 of 
sterile distilled water and its concentration determined against DNA of a known size. 
2.9.5.2 Big dye chain termination for sequencing 
Prior to sequencing the DNA, fluorescent dyes were incorporated into the purified DNA 
using the 2720 Thermal cycler from AB applied Biosystems. The reaction was carried 
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out according to the BigDye® tenninator v3.1 cycle sequencing Ready Reaction kit 
(Applied Biosystems). A cocktail was prepared containing 1).11 purified DNA (3-1Ong), 
1).11 of the sense (lOpmol) and the anti sense primer (lOpmol), 4).11 ofTTRM, 2).11 of the 
5x buffer (provided by the manufacturer) and sterile water making up a final volume of 
20).11. The cycling conditions were as follows: denaturation for 5mins at 96°C; 25 cycles 
consisting of 30sec denaturation at 96°C, 15sec annealing at 50°C and a final 4min 
extension at 60°C. The labelled samples were then analysed using the ABI PrismTM 377 
DNA sequencer. The ChromasPro package (Technelysium Pty. Ltd. Version 1.33) was 
used to analyse the sequences. 
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CHAPTER THREE 

CLINICAL DATA 

3.1 Adult sample collection 
Clinical data for adult patients with Tuberculosis (TB) (1) was obtained from G.F. Jooste 
hospital, a second tier hospital that drains patients from a huge community of poor socio­
economic background in an area commonly known as the 'Cape Flats'. South Africa's 
health care system has been restructured in accordance with the principles of Primary 
Health Care in which day clinics form the first tier. Hospitals such as G.F. Jooste are 
considered second tier centers that are both teaching hospitals and can act as referral 
hospitals to tertiary hospitals such as a university teaching hospital, where highly 
specialized care is provided. 
Initially a nursing sister accompanied us on our rounds to help mobilize patients to cough 
and produce sputum samples. Later a medical intern was recruited to facilitate access to 
newly admitted patients suspected of having TB. The intern ensured that fresh samples 
were collected from patients before they were placed on treatment and that samples were 
collected and stored in the cold as soon as possible and collected (on ice) and frozen at 
the earliest convenience. The sputum samples were collected in 6M guanidinium 
chloride (GuHCl) containing proteinase inhibitors, lOmM EDT A and 5mM NEM, and 
stored in a fridge at 4°C until we were able to collect them. The investigation was 
explained to the patients to gain their consent and a brief medical history was taken. The 
consent form is included as Appendix A. The TB diagnosis was made according to the 
criteria detailed in Appendix B. Sputa were collected on ice and a buccal swab taken 
from each patient after the mouth was rinsed with water. Procedures for extracting and 
analyzing the mucus were then followed as described in the Materials and Methods 
section (Chapter Two) whilst we waited upon the final diagnosis from the hospital. 
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3.1.1 TB diagnosis 

The medical diagnosis for TB was made on the criteria of AFB stain, culture, chest X­

rays (CXR) (Appendix B) for 21 subjects, 15 of whom were male and 6 female. The 

median age of subjects in total was 36. 

3.1.2 Criteria for diagnosis 

TB was diagnosed according to the criteria set out by the World Health Organization 

(WHO). Interfering variables that were thought to be responsible for exacerbating mucus 

production, were identified in study subjects. These included a history of cigarette 

smoking, alcohol consumption, substance abuse e.g. dagga and diabetes mellitus. The 

presence of other mucus - producing respiratory diseases such as bronchietasis, chronic 

obstructive pulmonary disease (COPD) and asthma were also recorded as these were 

expected to possibly interfere with mucus and mucin production. 

3.1.3 Diagnostic definitions 

The WHO diagnosis of TB is categorized as follows: 

a. 	 Possible: a patient is considered to be a possible TB subject when the clinical data 
and radiological results are in agreement with the consultant's diagnosis and the 
microscopy and culture results are negative. 
b. 	 Probable: this diagnosis is made when direct microscopy of sputum, lymph node 
aspirates and other samples are declared acid fast bacilli (AFB) positive. 
c. 	 Definite: a patient is diagnosed as TB positive when Mycobacterium tuberculosis 
is cultured from sputum or any other sample. 
Of the 21 adults present in the study, seven were defined as possible, four as probable and 
ten as definite, according to the WHO criteria. 
3.1.4 Other complicating variables 
The definite TB patients varied in their HIV status; they were diagnosed as positive, not 
suspected or negative. The majority of the definite cases were complicated with 
bronchiectasis alone, two HIV patients presented individually with COPD, and COPD 
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complicated with bronchiectasis and diabetes (Table 3.1). The probable TB patients were 
HIV negative; with one of the patients featuring with bronchiectasis (Table 3.1). The 
possible TB patients were also diagnosed as HIV positive, not suspected or negative and 
appeared to present mainly with bronchiectasis followed by COPD and asthma. None of 
the TB patients presented with interfering variables such as smoking, drinking or 
substance abuse. 
3.2 Children sample collection 
Collection of sputum from children, between the ages of 3months-5yrs, was carried out at 
the Red Cross Children's Hospital. HIV was a complicating factor in all the babies but 
was not found to interfere with TB diagnosis. Of the 69 HIV positive children from 
whom sputum was collected, 9 children were diagnosed as TB positive, 3 of which were 
on treatment, a single child had been treated for TB previously and 58 children were TB 
negative. The procedure involved intubation of the babies for tracheal mucus which was 
carried out by a nursing sister. The investigators were provided with buccal swabs for the 
DNA. The swabs and mucus were stored at 4°C until collected for lab investigation. 
Once collected the tracheal mucus were solubilised in 2.5ml 6M GuHCI and stored at 
-20°C for further use. Except for the TB diagnosis and HIV status further clinical data 
could not be obtained for the children. 
3.3 Discussion 
The sample number for TB positive adults was small to begin with as sample collection 
presented great difficulty during that period of the study. The additional help from a 
medical intern resulted in success with respect to sample collection but other factors 
appeared to create further obstacles, the main obstacle being that DNA samples could not 
be obtained from discharged or deceased patients. Nevertheless clinical data was 
obtained for 21 subjects involved in the study; of the 21 subjects the patients in table 3.1 
presented with significant results in the western blotting investigation (Chapter four). 
Sputum (especially induced sputum) was the sample of choice for cellular and 
biochemical analysis as it is found to be valid when monitoring airway inflammation 
(Gershman et al., 1999). Bronchiectasis appeared to be the major complicating factor in 
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the TB positive adults, especially the definite TB patients. This could be explained by 
studies which state that bronchiectasis is a late complication to TB (Andreu et al., 2004) 
hence a closer association with definite TB. 
With respect to sputum collection from children, samples were taken from an 
investigation that was already underway at the Red Cross Childrens Hospital. Dr Heather 
Zar, the coordinator of the study, established the reliability of the TB diagnosis, 
irrespective of the HN status of the children. Furthermore the study confirmed the 
clinical efficacy of sputum induction for TB diagnosis in children (Personal 
communication with Dr Zar). 
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Table 3.1 Adult Patients diagnosed with TB according to the WHO standard. 
Case 
number 
Gender and 
Age 
TB status HIV status Respiratory 
diseases 
Other 
variables 
1 Male 34 possible suspected none N/A 
3 Male 23 possible negative bronchiectasis 
COPD 
N/A 
*4 Female 3 1 pos ible positive asthma N/A 
8 Female 30 definite suspected N/A N/A 
9 Male 51 definite positive COPD N/A 
11 Female 15 definite Not 
suspected 
bronchiectasis N/A 
*13 Mal 35 probable negative bronchiecta is N/A 
*22 Female 15 definite Not 
su pee ted 
bronchjeetasi N/A 
*25 Male 35 possible p sitive N/A N/A 
*26 Male 49 po . ible Not 
u. pected 
bron hiecta is 
COPO 
N/A 
27 Female 66 defirute Not 
suspected 
bronchiectasis 
COPD 
diabetic 
28 Male 33 probable negative N/A N/A 
*30 Male 50 pos. ible Not 
u. pee ted 
bronch iecta. i N/A 
* The adult samples used for MUC2 detection during western blotting (Chapter 4.1) are 
highlighted in blue (definite and probable) and red ('possible' TB patients) and those 
used for MUC5AC and MUC5B detection are rughlighted in black. 
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CHAPTER FOUR 
AGAROSE GEL ELECTROPHORESIS AND WESTERN BLOTTING 
4.1 Identification of mucins by Western Blotting 
Crude (induced) sputa from 'healthy' (symptom free) volunteers (V), mucus scrapings 
from the tracheal tissue of cadavers (PM), and expectorated sputum samples from adults 
with TB (J) and from HIV positive children with TB (RC) were collected and solubilised 
in cold 4M GuHCI and proteolytic inhibitors. The disulphide bonds of the mucins were 
then reduced with 10mM DTT and alkylated with 2SmM IAA, to obtain mucin subunits 
with epitopes exposed for detection (Kirkham et al., 2002). The reduced mucin subunits 
were then loaded on a 0.7% agarose gel and electrophoresed to separate them on the basis 
of their charge. Equal volumes of samples from differ nt patients and groups were 
loaded onto the gel with the aim of detecting mucins of specific charge and the variety of 
'possible' glycoforms present for each mucin type. Following electrophoresis the 
samples were vacuum blotted onto nitrocellulose to affirm the presence of the dominant 
respiratory glycoproteins, MUCSAC and MUCSB (Kirkham et al., 2002), and to 
investigate the possible presence of any novel mucins being secreted in TB. Patients with 
suspected TB (group J) were classified according to the World Health Organization 
(WHO) classification as having 'definite', 'probable' or 'possible' TB (Chapter three, 
Clinical chapter). This study regarded the 'definite' and 'probable' TB patients as TB 
positive and compared these with those considered as 'possible' TB patients. The RX 
group was treated similarly. 
MUCSAC is a known mucin component in gastric mucus and secretions (Pinto-de-Sousa 
et at., 2004). Salivary mucus is a negative control for MUCSAC and the positive control 
for MUCSB (Veerman et al., 1996, Thornton et al., 1999). The specificity of the 
MUCSAC antibody LUMS-l, in the volunteer (V) blot (Figure 4.1), was confirmed 
against purified gastric cancer mucin (positive control, lane 1) and crude saliva (negative 
control, lane 2). There was very little or no MUCSAC in the induced sputum of the 
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volunteers (Figure 4.1, lanes 3-8). The trace amounts of crude material present in lanes 6 
and 8 (Figure 4.1) were in a comparable position on the gel to the larger amounts of 
MUC5AC in the sputa of TB positive adult patients (Figure 4.3, lanes 3-10). MUC5B 
appeared as dark, broadly smeared material in group V (Figure 4.2, lanes 3, 4, 7 and 8) 
almost covering the entire gel. Sample H (lane 5) and F (lane 6) had no MUC5B. 
Interestingly sample H had no MUC5AC either (Figure 4.1, lane 5). 
MUC5AC gave a single distinct band for sputa from each of the TB positive adults (J) 
(Figure 4.3) with a strong signal for purified gastric cancer mucin (positive control) 
(Figure 4.3, lane 1). The specificity of the MUC5AC antibody was supported not only by 
the positive control but also by the absence of this mucin in crude saliva (Figure 4.3, lane 
11). The position and appearance on the gel of MUC5AC in TB (Figure 4.3) is similar to 
that described by Thornton et al (1996), for patients with asthma and chronic bronchitis, 
and in a local study of asthma patients attending the Respiratory Clinic at Groote Schuur 
Hospital (Mall, personal communication). The difference in the position of the gastric 
cancer mucin on the gel (Figure 4.3, lane 1) compared to that of the respiratory mucins 
(Figure 4.3, lanes 3-10) could be attributed to the difference in charge of this mucin in 
two separate secretions in the body. 
MUC5B in the TB positive adults (J) (Figure 4.4, lanes 3-10) showed a similar 
electrophoretic mobility'to that of the volunteer (V) group (Figure 4.2, lanes 1-6) with the 
range of charged species somewhat less than that of the V group (Figure 4.2). As in the 
V group, inter-individual variation appeared to exist within the TB positive adults (J). 
Once again the specificity of the MUC5B antibody showed in its reactivity to the positive 
control (crude salivary mucin, Figure 4.4, lane 11), and the absence of this reactivity to 
the negative control (purified gastric cancer mucin, Figure 4.4, lane 1). The TB positive 
adults (J) appeared to be positive for both MUC5AC and MUC5B (Figures 4.3 and 4.4, 
respectively) as reactivity to the antibodies were detected in the same 8 adult samples 
(Figures 4.3 and 4.4, lanes 3-10). The appearance of MUC5B on the gels was different to 
that of MUC5AC (Figures 4.4 and 4.3, respectively) in that the MUC5B displayed 
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variation in terms of wider range of charge. A single TB positive patient was negative 
for both MUC5AC and MUC5B (Figures 4.3 and 4.4, lanes 2). 
The pattern of reactivity for MUC5AC (Figure 4.5) and MUC5B (Figure 4.6) in the RX 
group (HIV positive children with TB) were similar to that of the adult group with TB (J) 
(Figures 4.3 and 4.4). Again, MUC5B displayed a broad range of charge and MUC5AC 
appeared as a more distinct entity. Positive and negative controls (Figures 4.5 and 4.6, 
lanes 1 and 2) presented with a similar pattern to that seen in the V (Figure 4.1 and 4.2, 
lanes 1 and 2) and J (Figures 4.3 and 4.4, lanes 1 and 11) blots. MUC5AC in the RX 
group (Figure 4.5) appeared to travel slightly further into the gel in comparison to 
MUC5AC in group J, suggesting a slightly higher charged species in the children 
compared to the adults (Figure 4.3). MUC5AC was detected in 6 of the 10 TB positive 
children (Figure 4.5, lanes 3, 5, 7, 8, 9 and 11). MUC5B was detected in 8 of the 10 TB 
positive children (Figure 4.6, lanes 3-5 and 7-11). MUC5AC was not detected in two 
patients (Figure 4.5 lanes 6 and 12); the same patients (Figure 4.6, lanes 6 and 12) had 
very little MUC5B. 
Western blots comparing the control and diseased groups were probed with the MUC2 
antibody, LUM2-3 (Herrmann et ai, 1999). Figure 4.7 illustrates the absence or in the 
case of one patient (lane 4) a small amount of MUC2 material in the volunteer group 
(Figure 4.7, lanes 4,5 and 6). The positive control (purified colon mucin) appeared at the 
top and quite faintly in the middle of the gel (Figure 4.7, lane 1). MUC2 was detected in 
crude saliva from a healthy individual with severe sinusitis (Figure 4.7, lane 2). The 
MUC2 antibody detected purified mucin from a gastric cancer which appeared as a dark 
smear at the top of the gel (Figure 4.7, lane 3). In figure 4.7 (lanes 7-11) the TB positive 
adults and children show varying amounts of material at the bottom of the geL A TB 
positive adult (Figure 4.7, lane 7) and a TB positive child (Figure 4.7 lane 9) presented as 
dark prominent smears indicative of a high charge form of MUC2 (illustrated by arrows). 
A TB positive adult (lane 8) and child (lane10) and an adult with 'possible' TB (lane 11) 
also presented as fainter high charged bands of MUC2 (Figure 4.7, indicated by an arrow) 
at similar positions to the darker smears of MUC2 (Figure 4.7, lanes 7 and 9). The two 
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TB positive children also presented with faint traces of a low charge band (lanes 9 and 
10) (illustrated by circles). 
The positive control for MUC2 in figure 4.8, purified colon mucin, along with the 
purified gastric cancer mucin and crude salivary mucin (lanes 2, 1 and 3 respectively) 
were detected at the same positions in figure 4.7 (lanes 1, 3 and 2). Patients classified as 
having 'possible' TB and also being diagnosed with other non-TB respiratory problems 
(Figure 4.8, lanes 4-12) gave two distinct charges ofMUC2 which presented as a doublet 
of varying intensities. Although not clear in all samples, the doublet (illustrated by the 
red circle) appeared in each of the 'possible' TB samples (Figure 4.8, lanes 4-12) with the 
most distinct bands featuring in lanes 7 and 9 (Figure 4.8). The 'possible' TB subjects 
(adults) also presented with faint high charge bands in lanes 9, 10, 11 and 12 (Figure 4.8, 
indicated by arrows). It should be noted that the high charge form ofMUC2, presented in 
the TB positive adults and children (Figure 4.7, lanes 7-10), was barely discernable in the 
blots for patients who were 'possible' TB subjects (Figure 4.8, lanes 9, 10, 11 and 12). 
The volunteers (controls) had trace amonts (Figure 4.7, lanes 4,5) or no MUC2 (lane 6). 
MUC5B appeared as broad bands compared to MUC5AC in all four groups (groups V, 
N, J and RX). Glycoforms of MUC5B were not easily identified within the broad 
smears. In addition it was interesting to note that the respiratory sputa in this 
investigation differed in electrophoretic movement in comparison to the positive controls 
for MUC5AC and MUC2. MUC5AC detected purified gastric cancer mucin was 
identified at the top of the gel while the respiratory mucins sat in the middle of the gel 
(Figures 4.3 and 4.5). Mucin from a purified colon and gastric cancer probed for by 
MUC2 sat the top of the gel whilst MUC2 detected respiratory mucins were found in the 
middle and bottom of the gel (Figures 4.7 and 4.8). 
44 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
4.2 Discussion 
Western blotting was the method of choice as it has proven to be a widely used analytical 
tool in mucin detection (Dunn, 1986). This investigation made use of SDS-agarose gels 
during western blotting and not SDS-PAGE gels, although initially SDS-P AGE gels were 
the forerunners in the analytical study of mucin biosynthesis. SDS-PAGE gels highlight 
dispersity within each homogenous mucin population (Berry et at., 2000). Their intrinsic 
negative charge of mucins, imposed by sialic acid and sulphate residues at the terminus 
of O-glycans, interact with SDS to influence their mobility. Agarose gel electrophoresis, 
as described by Thornton et al (1997) was the method of choice in the separation of 
mucins in this study. SDS-PAGE gels are successful at separating lower molecular 
weight mucins such as MUC7. High molecular weight mucins (MUC5AC, MUC5B, 
MUC2), due to their degree of glycosylation and large size, are incapable of entering the 
polyacrylamide matrix. Agarose gels appear to optimally separate large charged and 
uncharged glycoproteins which can not penetrate SDS-PAGE gels (Tytgat et at., 1995). 
This is clearly observed in Figures 4.1-4.8. 
Reduction and alkylation was carried out on the sputum and scrapes prior to SDS-agarose 
gel analysis. This was a necessary preliminary step as respiratory secretions such as 
human bronchial mucus have a gel-like viscosity due primarily to mucin glycoproteins 
(Houdret et at., 1981). Its mucoid nature makes it problematic to work with, hence the 
reduction of mucins to generate subunits. This allows for the mucin subunits to enter 
agarose gels during electrophoresis. Reduction is also essential for antibody detection of 
mucin epitopes. This was observed in MUC5B detection of cervical secretions. Whole 
cervical mucins yielded a low reactivity to the MUC5B in comparison to its reduced and 
alkylated subunits. Salivary and respiratory mucins behaved similarly (Wickstrom et at., 
1998). It is further mentioned that the protein core of the mucin subunit is representative 
of the primary gene product making it even more advantageous to work with (Thornton et 
ai., 1995). Proteolysis was excluded from this study preventing cleavage to the protein 
core hence the attempt to maintain the protein structure as close as 'possible' to its in vivo 
state (Getz et at., 1999). 
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Personal experience and literature (Dunn, 1986, Gershoni et ai., 1983, Thornton et al., 
1994) have emphasized the importance involved in the stringency of the blotting 
procedure. The gels are incubated in transfer buffer to prevent swelling during the 
blotting procedure. If this step is omitted the gel swells during vacuum blotting resulting 
in distorted protein bands (Gershoni et al., 1983). Poly-L-Iysine aids greatly in the 
binding of the mucins to the nitrocellulose via an electrostatic interaction (Thornton et 
al., 1989). Background staining was successfully avoided as is seen in Figures 4.1-4.8 
by: 
a) careful handling of the gel during blotting 
b) the removal of bubbles between the membrane and gel during blotting 
c) the use of milk powder (non-fat) and Tween-20 in the blocking solutions (Dunn, 
1986) and antibody solutions 
d) extensive washing between the antibody incubation periods 
e) care taken during the ECL 
Western blotting presented with contrasting results after MUC5AC and MUC5B 
detection of the volunteer group (control group). MUC5AC was barely visible in the six 
volunteer samples (Figure 4.1). This experience has been the experience of other 
researchers (Dr John Sheehan, personal communication during a visit to laboratory in 
November 2005). This was significant as literature states that both the MUC5AC and 
MUC5B mucins are clearly present in normal healthy controls (Henke et al., 2004). It is 
suggested that MUC5AC exists in trace amounts in "healthy" individuals and that it was 
reduced even further during the stringent intermediate steps of the western blotting 
procedure previous to antibody detection. It is also hypothesized that antibody detection 
of these highly glycosylated mucins is increased during a diseased state due to a loss of 
certain sugar side chain residues and hence a greater exposure to, and antibody detection 
of the apomucin. This could explain why Rose and Voynow, (2006) found that 
MUC5AC and MUC5B "appear" at reduced levels in healthy airways compared to 
sputum from asthma, chronic bronchitis and cystic fibrosis (CF) patients. It is further 
suggested that an alteration in glycosylation could be a result of the TB mycobacterial 
invasion as in the case of Helicobacter pylori a bacterium reported to reversibly alter the 
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glycosylation patterns of gland mucus cell mucins (GMC) in the gastric mucosa 
(Matsuzwa et at., 2003). Gastric MUC5AC is known to present with a primary receptor, 
a blood group Leb oligosaccharide, for Helicobacter pylori in the stomach (Rose and 
Voynow,2006). Bacteria are also known to adhere to specific oligosaccharide sequences 
on intestinal mucins (Brockhausen, 2004). In contrast to MUC5AC, MUC5B was 
observed as distinct broad smears in 4 of the 6 volunteer (Figure 4.2, lanes 3,4, 7 and 8). 
Two of the six volunteers did not present with MUC5B (Figure 4.2, lanes 5 and 6). This 
could be explained by inter-individual variation within a 'normal' population although a 
greater number of samples would be required to support this line of argument. 
Prior to this study, investigations on mucins have been carried out in respiratory diseases 
such as CF, chronic bronchitis (CB) and asthma (Kirkham et ai., 2002). The results from 
this study correlate well with past respiratory studies as the major respiratory mucins, 
MUC5AC and MUC5B have been detected in TB positive adults and children (Figures 
4.3-4.6). The absence of MUC5AC and MUC5B in a single TB positive adult (Figures 
4.3 and 4.4, lane 2) and two TB positive children (Figure 4.5 and 4.6, lanes 6 and 12) 
could possibly be, amongst other reasons, explained by the subjects having a dry cough, 
hence the lack in sputum production. 
Past studies have emphasized the difficulty associated with the identification of MUC2 in 
normal and diseased respiratory tract secretions (Thornton et ai., 1997, Buisine et ai., 
1999, Davies et at., 1999). This study illustrated the absence of MUC2 in healthy 
volunteer samples (Figure 4.7, lanes 4-6) and its presence in TB positive and the 
'possible' TB adults and children (Figures 4.7, lanes7 -11 and 4.8, 1anes 4-12). Takeuchi 
et at (1995) hypothesized that MUC2 mRNA is expressed in various nasal diseases and is 
absent in normal, healthy nasal mucosa. This was confirmed by their studies which 
illustrated the expression of MUC2 mRNA during bacterial infection and stimulation via 
allergens, and its absence in a normal state. This could explain the absence of MUC2 in 
the volunteers (V) and its presence in the TB positive adults and children (Figure 4.7). 
Furthermore, it was suggested that the amount of MUC2 in the healthy volunteers was 
too low to detect (personal communication with Dr Annkatrin Herrmann). Asthma 
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studies have also illustrated a higher percentage of MUC2 during the diseased state in 
comparison to the healthy individuals (Rose and Voynow, 2006). The presence of 
MUC2 in the TB positive samples could be strongly related to the influence of the TB 
bacilli. This idea is supported by findings such as Kim etal (2003) who discovered that 
MUC2 gene expression in the airways was stimulated by an endotoxin from the gram 
negative bacteria, Pseudomonas aeroginosa. The TB bacilli could be playing a similar 
role to that ofPseudomonas aeroginosa by stimulating the MUC2 gene expression during 
TB. 
MUC5AC and MUC5B did not appear to present with glycoforms in both control and 
diseased groups. The MUC5AC results are consistent with literature as it is described as 
a homogenous species in comparison to the heterogeneous MUC5B (Kirkham et al., 
2002, Thornton and Sheehan, 2004). The MUC5B results are significant as they do not 
present with the well documented oligomeric glycoforms described by Thornton et al 
(1997), Sheehan et al (1999) and Kirkham et al (2002) as well as others. According to 
Thornton and Sheehan (2004), identification of individual mucin species requires the 
purification of reduced mucin preparations on a Mono Q anion exchange column. This is 
a well noted future consideration into the identification of glycoforms, especially 
respiratory MUC5B which is known to present with a low and high charge species 
(Thornton and Sheehan, 2004). MUC2 did exhibit varying bands depending on the TB 
diagnosis (Clinical Chapter, table 3.1). 
MUC2 was detected in the saliva of an individual with sinusitis (Figure 4.7, lane 2). 
Takeuchi et al (1995) have illustrated the expression of the MUC2 gene in the nose and 
paranasal sinus which could explain its presence in the crude saliva. It also presented as 
a prominent high charged broad band in a TB positive adult and child (Figure 4.7, lanes 7 
and 9). A similar, yet n<?t as prominent, band was found in a TB positive adult and child 
and a 'possible' TB adult (Figure 4.7, lanes 8, 10 and 11 respectively). The two TB 
positive children also presented with a low charge form of MUC2 (Figure 4.7, lanes 9 
and 10). MUC2 appeared as a pronounced doublet in adults and children categorized as 
'possible' TB patients (Figure 4.8, lanes 4-12). The 'possible' TB adults also presented 
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with faint traces of a high charge form (Figure 4.8, lanes 9, 10, 11 and 12). It is 
postulated that MUC2 appears as different glycoforms as TB progresses from the 
'possible' state to the probable and definite states. This theory is supported by the change 
in the intensity and presence of the high and low (doublet) charge bands. It is 
hypothesized that the high charge band appears as a weak signal during the 'possible' TB 
state and increases in intensity as definite TB is established; this is illustrated in the 
'possible' TB positive adults (Figure 4.8, lanes 9, 10, 11 and 12). Furthermore it is 
suggested that the doublet that features prominently in the 'possible' TB adults and 
children weakens to a faint barely visible band observed in the two TB positive children. 
This is supported by the presence of the faint low charge band in the TB positive child 
that also presented with the distinct high charged band (Figure 4.7, lanes 7 and 9). If this 
theory proves true then the MUC2 doublet could not only aid in diagnosis of TB but may 
also be related to a susceptibility to the disease. This would require further molecular 
studies as the hypothesized changes in the doublet and high charged form of MUC2 
suggests an alteration that is gene regulated. Literature has illustrated via molecular 
studies that longer MUC2 alleles in atopic non-asthmatics could be acting as a protective 
mechanism against the development of asthma (Vinall et al., 2000). 
The general broadened or smear like appearance of MUC5AC and MUC5B (Figures 4.1­
4.8) can be explained by oligomerization (which results in their high molecular weight), 
by microheterogeneity which is imposed by heterogeneous carbohydrate side-chains 
(Carlsson, 1993) and by the high levels of glycosylation of mucin itself, which could be 
up to 70% (Allen, 1981). MUC2 was also detected as a broadened band in the controls 
and in a TB positive adult and child (Figure 4.7 and 4.8). The varying intensity of the 
mucin bands within each blot is probably a result of the samples being loaded onto the 
gel as volume equivalents although studies such as those by Henke (2004) on cystic 
fibrosis secretions found that samples that were loaded onto gels at either the same 
concentration or volume were similar in appearance after MUC5AC and MUC5B 
detection. This suggests that the intensity of the mucin smears is not directly related to 
the concentration of the sample loaded into a gel. It is therefore hypothesized that a 
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darker smear could be indicative of a greater number of epitopes on a single mucin 
subunit. 
The electrophoretic differences observed between positive controls and samples are 
largely indicative of the differences in intrinsic negative charge. This similarity was 
observed by Thornton et at (199S). Human cervical, gastric, respiratory and salivary 
mucins were detected using a polyclonal antiserum raised to reduced mucin subunits. 
The mucins differed in terms of electrophoretic mobilities which were attributed to 
differences in their charge densities. This appears to be a similar case in this study. The 
MUCSAC detected purified human gastric cancer mucin has retarded mobility due to a 
lower intrinsic charge (Figures 4.3 and 4.S) (Tytgat et al., 1995) in comparison to the 
respiratory mucins. The MUCSB detected saliva appears to share a similar intrinsic 
charge with the respiratory mucins (Figures 4.2, 4.4 and 4.6). The MUC2 detected 
purified colon and gastric cancer mucins, appeared to have lower intrinsic charges in 
comparison to the high charged saliva and respiratory secretions (Figures 4.7 and 4.8). 
Respiratory MUC2 yielded 2 low charged species in the 'possible' TB state (Figure 4.8) 
and a single high charge species in the TB positive state (Figure 4.7). Furthermore 
MUCSAC in group RX (Figure 4.5, TB positive children) appeared to have a slightly 
higher charge than group J (Figure 4.3, TB positive adults). This could be related to 
differences in charge density and/or glycosylation between adults and children, and 
would therefore require deeper investigation. Future studies involving children would be 
problematic considering the difficulty associated in obtaining controls for children. 
so 
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Figure 4.1 0.7% Agarose gel electrophoresis of MUC5AC detected crude sputa from 
volunteers (V), used as controls in this study. Samples were reduced in 6M GuHCl, 
lOmM OTI for 5hrs and alkylated with 25mM IAA overnight. They were combined with 
agarose loading buffer (1 xTAE, 50% glycerol, bromophenol blue) and boiled for 90sec. Samples 
were run at 200A and 90V. They were then vacuum blotted onto nitrocellulose at a pressure of 
40-50bars. The primary antibody used is a MUC5AC, LUM5-1 (Hovenberg et ai., 1996) rabbit 
polyclonal and the secondary antibody is a goat anti-rabbit HRP. A 5rnin ECL was carried out 
for detection of protein bands. 
Lanes 1, purified gastric cancer mUCIn (positive control); 2, crude saliva (negative 
control); 3, Mari; 4, Z; 5, H; 6, F; 7, U ; 8, Mini 
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Figure 4.2 0.7% Agarose gel electrophoresis of MUC5B detected crude sputa 
obtained from volunteers (V), used as controls in this study. The samples were reduced 
in 6M GuHCl, 10mM OTT for Shrs and alk lated with IAA. They were combined with agarose 
loading buffer (lxTAE, 50% glycerol, bromophenol blue) and boiled for 90sec. The samples 
were run at 200A and 90V. They were then vacuum blotted onto nitrocellulose at a pressure of 
40-S0bars. The primary antibody used is a MUCSB, LUMSB-2 (Wickstrom et al., 1998) rabbit 
polyclonal. The secondary antibody is a goat anti-rabbit HRP. A Smin ECL was canied out for 
detection of protein bands. 
Lanes 1, crude saliva (positive control); 2, purified gastric cancer muclO (negative 
control); 3, Mari; 4, Z; 5, H; 6, F; 7, U; 8, Mini 
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Figure 4.3 0.7% Agarose of MUC5AC detected crude adult sputa (J). The samples 
were reduced in 6M GuHCl, 10mM OTT for 5hrs and alkylated with IAA. They were combined 
with agarose loading buffer (lxTAE, 50% glycerol, bromophenol blue) and boiled for 90sec. The 
samples were run at 200A and 90V. They were then vacuum blotted onto nitrocellulose at a 
pressure of 40-50bars. The primary antibody used is a MUC5AC, LUM5-1 (Hovenberg et ai., 
1996) rabbit polyclonal. The secondary antibody is a goat anti-rabbit HRP. A 5rrun ECL was 
carried out for detection of protein bands. 
Lanes 1, purified gastric cancer mucin (positive control); 2-10, TB positive adult 
samples; 11, crude saliva (negative control) 
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Figure 4.4 0.7% Agarose of MUC5B detected crude adult sputa (J). The MUCSAC 
blot (Figure 3) was stripped with mercaptoethanol and repro bed with a MUCSB, LUMSB-2 
(Wickstrom et al. , 1998) rabbit polyclonal. The secondary antibody was a goat anti-rabbit HRP. 
A Smin ECL was carried out for detection of protein bands. 
Lanes 1, purified gastric cancer mUCIn (negative control); 2-10, TB positive adult 
samples; 11, crude saliva (positive control) 
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Figure 4.5 0.7% Agarose of MUC5AC detected crude children sputa (RX). The 
samples were reduced in 6M GuHCl, 10mM OTT for 5hrs and alkylated with IAA. They were 
combined with agarose loading buffer (1 xTAE, 50% glycerol, bromophenol blue) and boiled for 
90sec. The samples were run at 200A and 90V. They were then vacuum blotted onto 
nitrocellulose at a pressure of 40-50bars. The primary antibody used is a MUC5AC, LUM 5-1 
(Hovenberg et at., 1996) rabbit polycional. The secondary antibody is a goat anti-rabbit HRP. A 
5rllin ECL was carried out for detection of protein bands. 
Lanes 1, crude saliva (negative control); 2, purified gastric cancer mUCIn (positive 
control); 3-12, TB positive children (RX) 
55 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
2 3 4 5 6 7 8 9 10 11 12 
Figure 4.6 0.7% Agarose of MUC5B detected crude children sputa (RX). The 
samples were reduced in 6M GuHCI, 10mM OTT for 5hrs and alkylated with IAA. They were 
combined with agarose loading buffer (lxTAE, 50% glycerol, bromophenol blue) and boiled for 
90sec. The samples were run at 200A and 90V. They were then vacuum blotted onto 
nitrocellulose at a pressure of 40-50bars. The primary antibody used is a MUC5B, LUM5B-2 
(Wickstrom et al., 1998) rabbit polyclonal. The secondary antibody is a goat anti-rabbit HRP. A 
5min ECL was carried out for detection of protein bands. 
Lanes 1: crude saliva (positive control); 2, purified gastric mucin (negative control); 
3-12, TB positive children (RX) 
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Figure 4.7 07% Agarose of MUC2 detected sputa. The samples were reduced in 6M 
GuHCI, 10mM OTT for 5hrs and alkylated with IAA. They were combined with agarose loading 
buffer (1 xT AE, 50% glycerol, bromophenol blue) and boiled for 90sec. The samples were run at 
400A and 65V. They were then vacuum blotted onto nitrocellulose at a pressure of 50-60bars. 
The primary antibody used is a MUC2, LUM2-3 (Herrmann et at., 1999) rabbit polycIonal. The 
secondary antibody is a goat anti-rabbit HRP. A 5min ECL was carried out for detection of 
protein bands. The black circles indicate the presence of a faint band present in lanes 9 and 10 
and the arrows point to the high charge form of MUC2. 
Lanes 1; purified colon mUCIn (positive control); 2, saliva; 3, purified gastric cancer 
mucin; 4-6, volunteer sputa (V), control; 7 and 8, TB positive adults (1); 9 and 10, TB 
positive children (RX); 11, 'possible' TB adult (1); 12, 'possible' TB child (RX) 
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Figure 4.8 0.7% Agarose gel of MUC2 detected sputa. The samples were reduced in 6M 
GuHCI, lOmM OTI for Shrs and alkylated with IAA. They were combined with agarose loading 
buffer (l xT AE, 50% glycerol, bromophenol blue) and boiled for 90sec. The samples were run at 
400A and 6SV. They were then vacuum blotted onto nitrocellulose at a pressure of SO-60bars. 
The primary antibody used is a MUC2, LUM2-3 (Herrmann et ai., 1999) rabbit polyclonal. The 
secondary antibody is a goat anti-rabbit HRP. A Smin ECL was carried out for detection of 
protein bands. The red circle highlights the MUC2 doublet and the arrows indicate faint high 
charge bands in lanes 9, 10 and 11). 
Lanes 1; purified gastric cancer mucin (positive control); 2, purified colon mucin 
(positive control); 3, saliva; 4-8, 'possible' TB positive children (RX); 9-12, 'possible' 
TB positive adult (1) 
58 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
• 
• 
CHAPTER FIVE 

MUCIN EXTRACTION AND PURIFICATION 

5.1 Solubilisation and purification of mucin 
Sputum samples and crude mucus scrapings were suspended in 6M GuHCI containing a 
mixture of proteinase inhibitors namely NEM and EDTA, in phosphate buffer, pH 6.5. 
Mucus scrapings were solubilised by brief homogenization and centrifuged at 1000 rpm 
(6000g) for 1 hour at 4°C, to remove insoluble debris. The supernatants were fractionated 
by two successive equilibrium density gradient centrifugations in CsCI, for 48h (starting 
density 1.420g/ml), at 105 OOOg (40 OOOrpm) in a Beckman centrifuge. Following 
ultracentrifugation the isolated mucin was SUbjected to SDS-PAGE analysis to confirm 
that it was free of contaminant protein, lipid and nucleic acids. 
Figure 5.1 illustrates the PAS, protein and density profile of the repiratory mucins after 
the first CsCI centrifugation. The profile presented with traces of protein contaminants, 
as can be observed from the protein peak at fraction 6 (indicated by the blue square), 
hence the need for a second CsCI purification. The mucins that peaked at approximately 
1.3-1.4g/ml (fractions 4,5 and 6) were pooled and prepared for a second purification. 
.. 
Figure 5.2 shows that the mucins are free of contaminant protein (the protein profile did 
not present with peaks) after two successive spins in a CsCI density gradient 
centrifugation. Mucin fractionated at a density of approximately 1.3-1.4g/ml in fractions 
4,5 and 6. 
-

An SDS-PAGE analysis of the purified and isolated mucins is illustrated by Figure 5.3. -

.. 	 The running gel was stained with Brilliant Coomassie Blue (BCB) to determine the 
presence of protein contaminants such as serum proteins and secretory glycoproteins 
-

(Bhaskar et al., 1981). After staining and de staining the High MWM was clearly 
I• 
 detected in lane 1. The lanes containing the purified respiratory mucin samples from 
• 
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groups V, J and RX groups (lanes 2-12) appeared blank. This indicated a lack of 
detectable protein in the isolated mucins. 
Figure 5.4 and 5.5 represent a TB positive post mortem (PM) scrape (lanes 3 and 4). 
Post-mortem samples (PM) were obtained early in this study due to the difficulty 
experienced in obtaining samples from 'normal' volunteers. The scrape was purified via 
a CsCI density gradient and was compared to its crude equivalent. Antibody detection 
for MUC5AC (Figure 5.4) and MUC5B (Figure 5.5) revealed clear, broad bands for both 
the crude (Figures 5.4 and 5.5, lane 3) and purified TB positive scrape (Figures 5.4 and 
5.5, lane 4) with a broader background to the unpurified material in each case. 
5.2 Discussion 
Mucins were extracted in a mixture of GuHCI and proteolytic inhibitors in order to 
minimize degradation through proteolysis, according to the method of Carlstedt and 
Sheehan (1984). EDTA was required to inhibit metalloproteinases (Carlstedt and 
Sheehan, 1984) and NEM served to prevent disulfide exchange (Sheehan et aI., 1981) 
and inhibit degradation via thiol proteinases (Carlstedt and Sheehan, 1984). Mucins were 
initially identified in crude sputum specimens by Western Blotting analysis. Some 
purified mucin was also analyzed by this method to determine whether association of 
mucin with protein and other components had any effect on separation by agarose gel 
electrophoresis. Purification and isolation of mucin was also necessary for amino acid 
analysis. 
Isolation and purification of mucins plays a pivotal role towards the understanding of 
their structure-function relationship. Various isolation techniques namely exclusion 
chromatography and ion-exchange chromatography have been employed in the past. The 
chosen purification technique of this study has also proved its worth in the isolation of 
mucins. The CsCI density gradient method has been well documented in studies 
involving the isolation of bronchial mucins, blood group substances, pig gastric and 
intestinal mucus and human gastric mucus (Woodward et aI., 1982). CsCI has also 
I 
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played a crucial role in the isolation of plant ribosomal DNA via the actinomycin-CsCI 
method (Hemleben et at., 1977). 
Mucins are well resolved in CsCI although better separated in caesium bromide (CsBr) 
(Bhaskar et at., 1981). CsCI is more often used due to its high diffusion constant, less 
viscous solutions and ability to create steeper gradients (Polson et at., 1963). The 
principle behind this method is that the mucins will find their isodensity as the 
sedimentation equilibrium is established. According to the Figures 5.1 and 5.2 the 
tracheal mucins sedimented around fractions 4, 5 and 6 at an approximate density of 
1.4g/ml. The isolation procedure was similar to that of Bhaskar et at (1981) hence 
agreeing with their statement that "mucus glycoprotein should be in the bottom half of 
the preparative tubes while all the protein should be the upper half'. This was 
demonstrated as the mucins were well separated from proteins, which appeared at greater 
concentrations in the higher fractions, and DNA which bands at approximately 1.63g/ml 
(Creeth, 1978). Separation from the protein fractions can be explained in terms of 
caesium's high ionic strength which is capable of breaking the strong non-covalent bonds 
that exist between protein-glycoprotein interactions (Allen, 1981) . 
According to Allen, (1981) SDS-PAGE analysis is a valid method in the determination of 
purity of mucins. The excellent resolution power of the SDS-PAGE highlights the purity 
of the second spin mucins (Figure 5.3). The MWM is well observed whereas all the lanes 
(except lane 3) containing the purified material appear blank. Lane 3 presented with a 
single band toward the bottom of the gel. This could be explained the presence of 
contaminating non-covalently bound, low molecular weight proteins which were absent 
in the other lanes (Allen, 1981). 
CsCI purification involves lengthy intermediate steps, requires the use of large quantities 
of reagents and involves two and even three 48-65hr ultracentrifugation spins. In this 
case we showed that CsCI purification was unnecessary to detect the relevant antigens for 
MUC5AC and MUC5B. The electrophoretic behaviour of the crude material, in terms of 
its broader mobility compared to purified material, could be explained by the 'age' of the 
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PM samples as cadavers were available only 48-72hr after death. Therefore in this case 
protein contamination and degradation are significant factors in explaining the slightly 
different electrophoretic behaviour the crude and pure sample. This resulted in the use of 
crude sputa throughout the western blotting investigation (Chapter 4) which was greatly 
beneficial to the study as both time and expense were reduced. A project of this nature 
could yield hundreds of samples and if purification of mucin was required there would be 
time, labour, financial and logistical factors to consider. 
The preparative mode of CsCI isolation is advantageous in that fractions can be 
quantitatively analysed (Bhaskar et al., 1981). This study produced satisfactory amounts 
ofpurified mucin for small scale analysis such as the amino acid analysis. The volunteer 
(V) and children group (RX) had the lowest mucin yield followed by the adult group (J). 
Studies on ''normal'' tracheal secretions such as group (V) are problematic due to the 
difficulty associated with sample collection (Woodward et al., 1982). The post mortem 
cadavers (PM) resulted in a greater number of samples with the highest yield of purified 
mucin. This could be explained by the fact that mucus was scraped directly from the 
epithelial lining of the trachea. The amount of scrapable material was also larger due to 
the increase of tissue degradation with time after death. With respect to the other groups 
the method by which mucus was collected allowed for greater contamination. 
CsCI is also known to operate in an analytical mode which allows for the identification of 
lipids and serum glycoproteins. Lipid and DNA analysis were not carried out on the 
purified samples and should be of future consideration. According to Woodward et al., 
(1982), "the contribution oflipid analysis to the overall architecture of mucus secretions 
cannot be overlooked". Lipid has been documented in the sputum of patients who suffer 
from varying bronchial diseases, and at elevated levels in the secretion of cystic fibrosis 
patients (Slayter, 1987). DNA analysis as observed from McLeod's (1992) study aids in 
the analysis of the step-by-step purification procedure and should be included in future 
investigations. 
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Figure 5.1 A PAS, protein and density profile of the first CsCl purification of 
respiratory mucus. Mucus was adjusted to a density of 1.39-I.4g/ml by the addition of solid 
caesium chloride and centrifuged at 40000rpm for 48hr at 4°C. The resultant gradient was 
fractionated into 8 equal parts. The density of each fraction was measured ( ), and following 
exhaustive dialysis of an aliquot against distilled water, each fraction analyzed for glycoprotein 
( . ) (PAS) and protein (.) (Lowry). The results are expressed as absorbance values and in glml 
for each fraction. 
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Figure 5.2 A PAS, protein and density profile of the second 48hr CsCl purification 
of respiratory mucus. Mucus was adjusted to a density of 1.39-I.4glrnl by the addition of 
solid caesium chloride and centrifuged at 40000rpm for 48hr at 4°C. The resultant gradient was 
fractionated into 8 equal parts. The density of each fraction was measured ( ), and following 
exhaustive dialysis of an aliquot against distilled water, each fraction analyzed for glycoprotein 
( . ) (PAS) and protein (.) (Lowry). The results are expressed as absorbance values and in glrnl 
for each fraction. 
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220K -. 
97.4K -. 
66K -. 
46K -. 
30K -. 
21.5K -. 
14.3K -. 
Figure 5.3 A 10% SDS-PAGE gel of CsCI purified samples. The samples underwent 
density gradient centrifugation twice, were dialysed and reduced in mercaptoethanol prior to gel 
electrophoresis. The gel was stained with Brilliant Coomassie Blue. 
Lane 1, MWM: the High molecular weight markers indicated by arrows in descending 
order are myosin (220K), phosphorylase b (97.4K), bovine serum albumin (66K), 
ovalbumin (46K), carbonic anhydrase (30K), trypsin inhibitor (21.5K), lysozyme 
(14.3K); Lane 2-13: purified respiratory mucin samples from V, J and RX groups 
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Figure 5.4 0.7% Agarose of MUC5AC detected crude post mortem scrapes (N). The 
samples were reduced in 6M GuHCl, 10mM DTT for 5hrs and alkylated with lAA. They were 
combined with agarose loading buffer (lxTAE, 50% glycerol, bromophenol blue) and boiled for 
90sec. The samples were run at 200A and 90V. They were then vacuum blotted onto 
nitrocellulose at a pressure of 40-50bars. The primary antibody used is a MUC5AC, LUM5-1 
(Hoven berg et al., 1996) rabbit polyclonal. The secondary antibody is a goat anti-rabbit HRP. A 
5min ECL was carried out for detection of protein bands. 
Lanes 1, purified gastric cancer mucm (positive control); 2, crude saliva (negative 
control); 3, crude TB positive scrape; 4, purified TB positive scrape 
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Figure 5.5 0.7% Agarose of MUC58 detected crude post mortem sputa (N). The 
MUCSAC blot (Figure 9) was stripped and repro bed for MUCSB, LUMSB-2 (Wickstrom et al., 
1998). The secondary antibody is a goat anti-rabbit HRP. A Smin ECL was carried out for 
detection of protein bands. 
Lanes 1, purified gastric cancer mUCIn (negative control); 2, crude saliva (positive 
control); 3, crude TB positive scrape; 4, purified TB positive scrape 
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CHAPTER SIX 

ACID AMINO ANALYSIS 

6.1 High pressure liquid chromatography (HPLC) analysis of amino acids 
Purified unreduced mucins were selected from the control groups (V and N) and TB 
positive groups (J and RX) for HPLC analysis. Altogether, two samples were selected 
from the volunteer group (V), three from the post mortem group (PM), two from the TB 
positive adult group (1) and two from the TB positive children group. The samples were 
hydrolysed to remove the carbohydrate chains from the mucin peptide and were placed 
on a HPLC column to elute the primary amino acids. 
Table 6.1 represents an average of the amino acid values for samples within each group. 
Glycine, threonine, serine, proline and alanine constituted 54.99 mol% of the volunteer 
group (V), 43.35 mol% of the PM group, 46.58 mol% of the TB positive adults (1) and 
48.94 mol% of the children (RX). 
Serine and threonine combined appeared at 22.38 mol% in the V group and at 16.01 
mol% in the PM group. Although the TB positive adults and children (18.37 mol% and 
17.17 mol% respectively) had slightly lower serine and threonine values compared to the 
volunteer group, they compared closely to each other. 
Serine, threonine and proline (PTS) accounted for 34.67 mol% in the V group, 22.88 
mol% in the PM group, 29.55 mol% in the J group and 29.31 mol% in the RX group. 
The PTS mol% was approximately 5% higher in the healthy volunteers (V) compared to 
the TB positive adults (1) and children (RX), who presented with similar values. 
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6.2 Discussion 
Amino acid analysis was carried out to detennine the composition of the respiratory 
apomucins from the control (V and N) and TB positive groups (1 and RX). This was 
expected to lend insight into similarities or differences between the amino acid 
compositions from each group. According to Woodward et al (1982), a high amino acid 
combination of glycine, alanine, threonine, serine and proline is characteristic of the 
typical mucin composition. This combination in the V group (54.99 mol%) compared 
well with the findings of Woodward et al (1982) who presented with a 54 mol% 
combination in bronchial aspirates of patients without pulmonary diseases. This is also 
similar to the findings of Bhattacharyya et al (1990) who claimed that the glycine, 
threonine, serine, alanine and proline accounted for 50-60 mol% of the total bronchial 
amino acid composition. In contrast to the volunteer group, the PM, 1 and RX group 
presented with much lower values of the amino acid combination (43.35 mol%, 46.58 
mol% and 48.94 mol% respectively). Respiratory diseases such as CF and asthma have 
presented with higher percentages (63 mol% and 57 mol% respectively) (Chace et al., 
1985) of the amino acid combination compared to the TB diseased groups. Chace et al 
(1989), like Bhattacharyya et al (1990), found that the glycine, threonine, serine, alanine 
and proline represented 71 mol% of CF mucins compared to the 61 mol% in nonnal 
mucins. In contrast this study found that the V group (nonnal healthy controls) presented 
with an amino acid combination which was approximately 10% higher than the TB 
positive groups (group 1 and RX). Similarly the PTS, and serine and threonine 
combination for the V group appeared higher compared to the 1 and RX groups. The 
differences observed in the PM group could be accounted for by proteolytic degradation. 
As suggested by Chace et al (1985), the differences observed in mol% between the TB 
groups and the control groups, and the TB groups and the CF and asthma studies could be 
related to "differences in the proportion of the different types of mucins present in the 
respiratory secretions". It is hypothesized that the level of secretion of respiratory mucins 
from different cell types (such as the goblet cells or submucosal glands) differs between 
healthy and diseased individuals. This hypothesis is extended to differences in the 
proportion of varying mucin types between respiratory diseases. 
69 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
The hydroxyamino acids serine and threonine are of particular importance as they 
represent the sites at which O-glycosylation takes place (Hovenberg et al., 1997). A 
combination of serine and threonine constituted approximately 20% of the total amino 
acid composition in each group (Table 6.1). This value compares closely to the serine 
and threonine range in previous studies (Mall et al., 1999). The TB positive adults and 
children appeared to share similar serine and threonine values (18.37 mol% and 17.17 
mol% respectively). Although not drastically different, these values are slightly lower in 
comparison to the volunteer group (22.38 mol%). It is postulated that the minor decrease 
in the serine and threonine composition of the TB positive groups is due to bacterial 
invasion. Based on previous studies it is hypothesized that the TB bacterium has a 
greater affinity for the sugar side chains of respiratory mucins compared to the amino 
acids of the protein backbone. According to literature certain carbohydrates present with 
epitopes that are possible sites of attachment for microbes and viruses (Lamblin et al., 
2001, Voynow, 2002). Literature has also associated glycosylation changes with 
bacterial invasion; Helicobacter pylori has been reported to reversibly alter the 
glycosylation of gastric mucins (Matsuzwa et ai., 2003). The change in amino acid 
composition could be secondary to the TB bacterium's interaction with the sugar side 
chains. The high proline content of the V, J and RX group is suggestive of a closely 
packed protein backbone. According to Allen (1981) this enables "the close packing of 
large carbohydrate side chains" hence their protection from proteolytic enzymes. 
It is observed from past studies (Chace et al (1989), Bhattacharyya et al (1990) that 
serine, threonine and proline are present at high percentages in comparison to the other 
amino acids that constitute the protein backbone (Thornton et al., 1996). Table 6.1 
reflects higher percentages of glycine and glutamic acid compared to serine, threonine 
and proline. It is suggested that the purified mucins were not fully deglycosylated as was 
discovered by Perini et al (1989), hence the greater mol percentage of glycine and 
glutamic acid. From their study it was illustrated that trifluoromethane sulfonic acid 
(TFMS) alone led to incomplete deglycosylation of human bronchial mucins hence the 
use of TFMS/anisole mixture and solvolysis in hydrogen fluoride (HF). The 
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deglycosylation process of the purified control and TB positive mucin samples using 
HCl, phenol and nitrogen gas was probably inefficient. 
Future studies should focus on isolating and purifying respiratory MUC5AC, MUC5B 
and MUC2 from control and diseased groups and thereafter carrying out amino acid 
analyses. This would better illustrate direct amino acid changes to specific mucin types 
within control and TB groups. Furthermore, a comparison of the amino acid and sugar 
analysis of a specific mucin type might lend insight into the presence and differences 
between mucin glycoforms. This would determine if it is the peptide backbone or sugar 
side chain that undergoes changes during the diseased state. One might also identify 
simultaneous alterations to both the protein backbone and sugar side chain hence 
revealing varying and unique amino acid sequences and O-glycosylation patterns 
explaining the heterogeneity between mucins (Voynow, 2002). It is also suggested that 
cysteine analysis be carried out as this would lend insight into cysteine rich domains 
which are major features of the tandem repeat regions of respiratory MUC5AC and 
MUC5B (Rose and Voynow, 2006). 
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Table 6.1 The mean amino acid composition (mol %) of deglycosylated respiratory 
mucin peptides. 
Amino acid 
Asp 
Thr 
Ser 
Pro 
Giu 
Group V 
(mol%) 
6.89 
11.25 
11.13 
12.29 
12.01 
Group PM 
(mol%) 
8.47 
8.69 
7.32 
6:87 
10.66 
GroupJ 
(mol%) 
7.83 
10.34 
8.03 
11.18 
13.02 
GroupRX 
(mol%) 
9.20 
8.49 
8.68 
12.14 
13.82 
I 
i 
I 
I 
Gly 
Ala 
Val 
13.45 
6.87 
5.07 
9.90 
10.57 
7.27 
10.99 
6.04 
5.58 
12.11 
7.52 
5.47 
I 
I 
! Met 0.30 1.38 1.22 1.15 
lie 
Leu 
Tyr 
Phe 
Lys 
Arg 
Total 
2.41 
5.43 
2.27 
1.91 
3.97 
4.74 
100 
2.54 
9.33 
2.12 
4.09 
6.57 
4.23 
100 
2.67 
6.29 
2.18 
2.36 
4.72 
7.55 
100 
2.33 
6.58 
3.03 
3.08 
4.13 
2.26 
100 
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CHAPTER SEVEN 

THE MOLECULAR STUDY 

7.1 The study group 
Of a total of 55 adults and children who were recruited for this study, thirty three were 
investigated for the MUC2 polymorphism and all were screened for the MUC5B 
polymorphism. The adults ranged between 14 and 66 years of age and the children were 
between the ages of 4 months and 6 years. The study group was further categorized into 
21 TB positive, 16 TB negative and 18 undetermined diagnoses. The TB positive group 
comprised 'possible', probable and definite TB individuals, as classified by the World 
Health Organisation (WHO). Regions of the MUC2 and MUC5B genes were amplified 
and investigated for known polymorphisms. 
7.2 Identification of the MUC2 polymorphism 
The MUC2 PCR products were digested with Pvull which recognizes a polymorphism at 
the 5' end of exon 11. The Pvull digestion of MUC2 is represented schematically in 
figure 7.1. In the absence of the polymorphism, Pvull cleaves the uncut 748bp PCR 
product into two fragments of 299bp and 449bp and represents the G allele. If the 
polymorphism at exon 11 is present then the 449bp fragment is further cleaved into a 
383bp and 66bp fragment which represents the C allele. 
Both the C and G alleles were seen in the study sample (Table 7.1). Of the 33 individuals 
investigated 12 (36%) were homozygous for the G allele compared to only 6 (18%) who 
were homozygous for the C allele. Fifteen (45%) of the 33 were heterozygous for the 
MUC21PvuII polymorphism. 
Categorisation of the sample on the basis of TB status showed that 8 of the 20 (40%) TB 
positive individuals were homozygous for the G allele, 6 (30%) were homozygous for the 
C allele and the remaining 6 (30%) were heterozygous for the two alleles. In contrast 
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none of the 12 TB negative individuals were homozygous for the C allele, only a third 
was homozygous for the G allele and the majority (66.7%) was heterozygous for both 
alleles (Table 7.1). 
In the total study sample the G allele appeared at a frequency of 59.1 % and the C allele at 
a frequency 40.9% (Table 7.2). Categorisation according to TB status showed similar 
frequencies for the G (55%) and C (45%) alleles in the TB positive individuals. In 
contrast, the TB negative group had a considerable lower frequency of the C allele (33%) 
compare to the G allele (67%). 
7.3 Identification of the MUC5B polymorphism 
The primers for MUC5B were designed to amplify across the VNTR region of intron 36 
which contains variable number of tandem 59bp repeats. Electrophoresis of the 
amplified VNTR region revealed seven different fragment sizes and eleven different 
genotype combinations, nine of which are observed in figure 7.3. Allele sizes were 
estimated by comparison against the band sizes of a 1kb MWM. Accurate sizing of 
fragments was undertaken by direct sequencing of the fragments to determine the number 
of repeats present within each allele. The 59bp repeats reported by Desseyn et al (1999) 
were illustrated in the sequenced MUC5B electrophoretic fragments (Figure7.4 
chromatogram). 
The MUC5B alleles appeared at 360, 420, 480, 540, 600, 660 and 720bp containing 4, 5, 
6, 7, 8, 9 and 10 59bp repeats, respectively (Table 7.3). The 8 repeating unit repeat had a 
frequency of 59.5% within the TB positive group and 50% within the TB negative group 
(Table??). Numerous allele combinations were seen in this study (Table 7.4) with the 8/8 
and 8/6 combinations of repeat units appearing at the highest frequencies in both the TB 
positive and negative groups. The genotypes observed in the TB positive group were 8/8, 
8/6, 817, 6/6, 7/6, 9/8 and 8/5, with the 8/8 presenting at the highest frequency in 8 of 
21(38.1%) individuals. The allele combinations present within the TB negative 
individuals were 8/8, 8/6, 7/6, 9/6, 10/6 and 6/5bp, with the 8/6 combination presenting at 
the highest frequency in 8 of 16 (50%) individuals (Table 4.5). 
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7.4 Discussion 
On the basis of previous European studies (Desseyn et ai., 1999, Vinall et ai., 2000) a 
small scale investigation on MUC2 and MUC5B polymorphisms was carried out in a TB 
suspected community of the Western Cape. Although the sample size was too small to 
make definite correlations between TB and allele frequencies and allele proportions of 
the groups in question, it did illustrate a difference between the TB positive and negative 
groups for the MUC2/PvuII polymorphism, with 30% of the 20 positive cases being 
homozygous for the polymorphism in contrast to its absence in the 12 TB negative 
individuals. As a result, the C allele appeared at a higher frequency (45%) in the TB 
positive cases than in the other group. The findings of the pilot study suggest that the C 
allele may result in a genetic predisposition to TB. According to Vinall et ai (1998), 
analyses of the MUC2, MUC6, and MUC5AC genes presented with high levels of 
heterozygous VNTR polymorphisms. This is of interest as most mucin genes have high 
levels of genetically determined polymorphisms (Vinall et aI., 2000, Rose and Vinall, 
2006) which have been associated with respiratory diseases. This was illustrated by 
length variations of MUC2 in asthma were "longer" MUC2 alleles were suspected of 
protecting predisposed individuals from the development of asthma (Vinall et ai., 2000). 
Cystic fibrosis studies support the upregulation of the transcription of MUC2 gene in 
response to pathogens such as Pseudomonas aeruginosa (Buisine et ai., 1999). It is 
suggested by Vinall et ai (2000), that allelic differences are associated with the amount of 
MUC2 secreted during inflammatory diseases such as cystic fibrosis. They further claim 
that the allelic difference could be related to a linked polymorphism within the MUC2 
gene or the length of the MUC2 RNA transcript. This study therefore warrants further 
investigation on a larger study sample to investigate the allele frequencies in the general 
South African population and in larger TB-prone populations in the country. 
This Western Cape study revealed similar repeat sizes to that found in Europe (Desseyn 
et ai., 1999) with variations in the number of repeat sizes and the number of allele 
combinations. Compared to their results of five alleles and seven genotypes that were 
found in 172 individuals, our study presented with 7 alleles (Table 7.3) and 11 genotypes 
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(Table 7.5) in only 55 individuals. The 7 repeating unit dominated in Desseyn's 
European population, whereas the 8 repeating unit dominated within the sample group of 
the Western Cape, especially within the TB positive individuals. Although the 8/8 
combination was common to the entire group it appeared more frequently in the TB 
positive group compared to the TB negative group . 
. 
The 10 repeating unit is also of interest as it was not reported by Buisine et al (1998) 
(who reported a maximum of 9 repeats of the 59bp) and Desseyn et al (1999) with a 
maximum of 5 repeats. This is of interest as the 10 repeating unit appeared in a single 
TB negative individual and not in the TB positive group. Furthermore Desseyn et al 
(1999) presented with a 3 repeating unit of the polymorphism which was absent in this 
study. Conversely this study illustrated the presence of 4 repeating units of the 
polymorphism which was absent in the Desseyn et al (1999) study. Based on these 
findings the TB study could be expanded to determine if the 8 repeating unit and its 
homozygous state remain at a higher frequency within the TB positive group of the 
Western Cape population and to investigate the frequency of the 10 repeating unit. 
Desseyn et al (1999) discovered that intron 36 ofMUC5B repeat is structurally similar to 
intron 6 of human interleukin-1 a, which also houses several repeats of 46bp. The human 
interleukin-1a polymorphism is associated with gene function as each repeat has three 
potential binding sites for transcriptional factors. It was suggested that this 
polymorphism is linked to the complex regulation of IL-1a gene transcription and, based 
on their similarities, that the MUC5B polymorphism could also playa similar role in 
gene regulation. Gene regulation studies could also lend insight into the cytokine 
mediated upregulation of the MUC5B gene in the TB positive and negative samples as 
the upregulation of MUC5AC and MUC5B by IL-17 is suggested to be specific to 
inflammatory or immune mediators (Rose and Voynow, 2006). 
An investigation into the expression of the MUC5B polymorphism in TB is warranted by 
past studies which identified MUC5B mRNA gene products at increased concentrations 
in lung mucus of asthmatic patients (Rose et al., 2001, Voynow, 2002). According to 
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Voynow et al (2002), a variation in the number of 59bp repeats at intron 36 could be 
related to MUC5B expression. MUC5B has also been expressed in respiratory diseases 
such as COPD and Diffuse Panbronchiolitis (DPB). An insertion/deletion polymorphism 
within the MUC5B promoter region was closely associated with DPB, a genetic disorder 
that afflicts mainly the Asian population (Kamio et aI., 2005). As in the DPB study a 
deeper investigation into MUC5B polyniorphisms at large could also lead to information 
regarding the genetic susceptibility and pathogenesis of TB within the Western Cape. 
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748 bp
a. MUC2 PCR 
product 
b. 
299 bp r 449bp 
x G allele 
Pvu II 
C allele 
c. 
299 bp f 383 bp f 66 bp 
Pvu II Pvull 
Figure 7.1 Illustrates the results of Pvull enzyme digestion of the MUC2 PCR 
products. a. represents the uncut MUC2 PCR product at 748bp b. if the RFLP is absent Pvull 
cleaves the G allele once to produce a 299bp product and 449bp product and c. Pvull cleaves the 
C allele twice to produce the 294bp, 383bp and 66bp products. 
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2 3 4 5 6 7 8 

748bp 
449bp 
383bp 
299bp 
Figure 7.2 A 2% agarose gel illustrating the results of Pvull enzyme digestion of the 
MUC2 PCR products. a. represents the uncut MUC2 PCR product at 748bp b. if the RFLP is 
absent Pvu II cleaves the PCR product once to produce a 294bp product and 449bp product and c. 
Pvu II cleaves the C allele twice to produce the 294bp, 383bp and 66bp products. 
Lanes 1, uncut MUC2 PCR product (control); 2, MWM; 3, CIC; 4, CIC; 5, GIG; 6, CIG; 
7, GIG; 8, CIG 
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Table 7.1 MUC2 C and proportions in the TB positive, negative and 
undetermined groups. 
TB Status 
TB 
C 
( 
G 
Allele (%) 
CG 
Allele 
6(30%) 
Total 
of 
TB negative 8(66.7%) 
Status 
undetermined 
Total 6(18%) 12(36%) 
1(1 
15(45%) 
1 
Table MUC2 C and G allele frequencies in the TB positive, and 
undetermined 
C 
) 
G 
Allele (%) 
Total 
of 
TB positive 18(45) 22(55) 40 
TB 8(33) 16(67) 24 

1(50) 1(50) 2 
Total 27(40.9) 39(59.1) 66 
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2 3 4 5 6 7 8 9 10 11 12 13 

1000 ---+­
700 ---+­
300 ---+­
800 
400 
Figure 7.3 A 2% agarose gel of the amplified VNTR region within MUC5B 

illustrating 9 genotypes along with the 8 alleles. The peR products containing 4, 5, 6, 7, 

8, 9 and 10 59bp repeats are 360, 420, 480, 540, 600, 660, nObp respectively. The circles 

illustrate the first allele at 360bp (4 repeats) and the seventh allele at nObp (10 repeats). The 

positions of the 1000, 800, 700, 400 and 300bp bands comprising the MWM are indicated by 

arrows. 

Lanes 1, MWM; 2, has 8 and 7 repeat; 3, has 6 and 8 repeats; 4, has 6 and 8 repeats; 5, 

the two alleles have 6 repeats; 6, has 6 and 9 repeats; 7, has 6 and 8 repeats; 8, 5 and 8 

repeats; 9, 3 and 10 repeats; 10, 4 and 6 repeats; 11, 12, blank; 13, MWM 
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Table 7.3 Allelic at 36 of the MUC5B in 55 
individuals. 
Desseyn's study 
Number size N N (total Frequency 
of (bp) (total (bp) 110) 
repeats 172) 
3 280 8 
2 0.018 
5 400 10 3 0.027 
6 450 2 34 0.309 
7 500 141 7 540 7 0.063 
8 11 0.064 8 600 59 0.536 
9 660 4 0.036 
10 720 1 0.009 
Table 7.4 The frequencies of the units within the TB positive, negative and 
undetermined groups 
Repeat Size (bp) 
(%) 
TB negative 
(%) 
Undetermined 
4 360 0 0 2 
5 420 1(2.4) 1(3.12) 1 
6 480 12(28.6) 12(37.5) 9 
7 540 3(7,14) 1(3.12) 3 
8 600 ?')(59.5) 16(50) 18 
9 660 1(2.4) 1(3.12) 3 
10 720 0 1(3.12) 0 
Total 42 32 36 
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Table The genotypes for the TB positive, negative undetermined 
individuals. 
Individual Genotype TB status Individual Genotype TB status 
1 8/6 Positive 29 8/8 Negative 
2 8/8 Positive 30 8/6 Positive 
3 817 Positive 31 8/6 NI 
4 f8!6 Positive 32 7/6 Positive 
5 Negative 
33 :-t NI ~6 Positive 34 Negative 
7 v Positive ~~ Positive 
3 I Negative8 8/8 Positive I 
9 6/6 Positive 37 8/t:. I Negative 
10 7/6 Positive 38 8/8 Negative 
11 8/8 Positive 39 10/6 Negative 
12 8/8 Positive 40 9/8 Undetermined 
3 8/8 Negative 41 6/4 Undetermined 
14 Positive 42 8/6 Undetermined 
9/6 Negative 43 8/6 Undetermined 
16 8/6 Negative 44 8/6 Negative 
17 9/8 Positive 45 8/6 Negative 
18 8/5 Positive 46 6/4 Undetermined 
-
19 8/8 Positive 47 7/6 Negative 
20 8/6 Positive 48 7/6 Undetermined 
21 8/8 Positive 49 6/5 Negative 
22 8/8 Undetermined 50 6/6 Undetermined 
23 8/5 Undetermined 51 817 Undetermined 
24 8/8 Undetermined 52 8/8 Undetermined 
25 9/8 Undetermined 53 8/6 U ndetermi ned 
26 8/8 -,. 54 8/6 U ndetermi ned • 
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Individual Genotype TB status Individual Genotype TB status 
27 9/8 Undetermi ned 55 8/8 Undetermined 
28 817 Undetermined 
Table 7.6 The MUC5B allele combinations within the TB positive, negative and 
undetermined groups. 
Genotype TB Positive (%) TB negative (% ) Undetermined 
8/8 8(38.1 ) 4(25 .0) 4(22.2) 
8/6 6(28.57) 8(50) 4(22.2) 
817 1(4.76) 0 2(11.5) 
6/6 2(9.52) 0 1(5.56) 
7/6 2(9.52) 1 (6 .25) 1(5 .56) 
9/8 1(4.76) 0 3(16.67) 
8/5 1(4.76) 0 1 (5.56) 
9/6 0 1 (6.25) 0 
10/6 0 1 (6.25) 0 
6/5 0 1 (6.25) 0 
6/3 0 0 2(11.1) 
Total 21 16 18 
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C CT G T G C GG T GAG T GGGGGCGG CCCC GGG C CCCr CAGA CC L CTr GG LCTCTCT GAG T GT 

Figure 7.4 the Chromatogram of the S9bp polymorphism within intron 36 of the 
MUCSB gene. 
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CHAPTER 8 
CONCLUSION 
8.1 The biochemical study 
Mucus is the body's first line of immune defence against various pathogens and irritants. 
It lines the epithelial layer and is in direct contact with bacteria, viruses, fungi, inhaled 
tobacco smoke and air pollution. Mucins, glycoproteins within mucus confer upon 
mucus their rheological, physicochemical and biological properties. It is in response to 
stimuli that mucin genes are upregulated resulting in the hypersecretion of mucus and 
mucin glycoproteins (Basbaum et al., 2002). Although hypersecretion is probably a 
defence mechanism against the pathogen, it does result in pathological changes such as 
goblet cell hyperplasia and metaplasia due to an excessive production of mucus. Mucus 
hypersecretion is of great concern due to the severe morbidity and mortality rates 
associated with respiratory diseases such as cystic fibrosis, chronic obstructive 
pulmonary disease and asthma. Antibody detection of the prominent respiratory mucins 
MUC5AC and MUC5B have illustrated their presence in healthy individuals. They have 
also been detected in various respiratory diseases but contrasted in appearance or 
concentration. From literatur  it is known that their sugar side chains behave as receptors 
for various bacteria, such as Streptoccoci. 
TB is a respiratory disease that spreads via the bacterium Mycobacterium tuberculosis. 
Its growth rate in Africa (6%) is currently the highest globally (Walzl, 2004). TB is rife 
within South Africa, specifically the Western Cape. It is a disease that preys on the 
impoverished communities (Munch et al., 2003) due to the lack of medical resources and 
the growth of HIV-AIDS (Bradshaw et al., 2002). Respiratory mucins have been 
associated with various respiratory diseases but not TB. 
The biochemical study focused on the characterization ofrespiratory mucins in adults and 
children with TB. MUC5AC and MUC2 were barely visible in the volunteer group 
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(controls) compared to MUC5B. The presence of MUC5AC and MUC5B was 
confirmed in the TB positive groups of this study. The results compared well with 
literature as respiratory MUC5AC and MUC5B have been observed at varying 
intensities, in terms of their appearance in western blots, in both healthy and diseased 
states. Besides the presence of the dominant respiratory mucins, MUC5AC and MUC5B, 
MUC2 was also detected in the TB adults and children. The LUM2-3 antibody kindly 
donated to us by Dr Sara Kirkham of Manchester, UK was used to identify the MUC2 
glycoforms in TB and non TB chest disease patients. Upon presentation of the MUC2 
results at the 8th International Workshop on Carcinoma-associated Mucins in 2005 by 
Professor Mall (Govender et al., 2005) a question was raised by Professor Ingemar 
Carlstedt and Dr Annkatrin Herrmann about the nature of the band at the end of the gels 
for MUC2 in TB patients (Figure 4.7 and 4.8, lanes 7-11 and 9-12 respectively). Dr 
Herrmann subsequently supplied us with an affinity purified LUM2-3 against MUC2 
(Herrmann et al., 1999) to confirm the presence of the above mentioned band. This did 
not work in our hands. In November of 2005, Dr John Sheehan visited our labs and 
suggested that the agarose gel, after electrophoresis, be incubated with 10mM DTT prior 
to blotting. This also failed to produce any results. The presence ofMUC2 in TB will be 
further investigated as part of a PhD project as it could yield a wealth of information 
concerning diagnosis and susceptibility to TB. 
Unlike MUC2, MUC5AC and MUC5B did not appear as different glycoforms. Past 
literature has reported the presence of two MUC5B glycoforms in respiratory studies 
(Thornton et al., 1997, Sheehan et al., 1999 and Kirkham et al., 2002). Antibody 
detection of MUC5B in the controls and TB samples presented as smears that did not 
reveal different glycoforms. Identification of the glycoforms would probably require 
purification of reduced mucin preparations on a Mono Q anion exchange column as 
suggested by Thornton and Sheehan (2004). This might lead to similar findings as by 
Kirkham et al (2002) who discovered that the more acidic form of MUC5B was found in 
healthy airways in comparison to CF and COPD airways. We have just procured funding 
for an HPLC system. 
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The biochemical study focused on the characterization of respiratory mucins in adults and 
children with TB. MUC5AC and MUC2 were barely visible in the volunteer group 
(controls) compared to MUC5B. The presence of MUC5AC and MUC5B was 
confirmed in the TB positive groups of this study. The results compared well with 
literature as respiratory MUC5AC and MUC5B have been observed at varying intensities 
in healthy and diseased states. Besides the presence of the dominant respiratory mucins, 
MUC5AC and MUC5B, MUC2 was also detected in the TB adults and children. The 
LUM2-3 antibody kindly donated to us by Dr Sara Kirkham of Manchester, UK was used 
to identify the MUC2 glycoforms in TB and non TB chest disease patients. Upon 
presentation of the MUC2 results at the 8th International Workshop on Carcinoma­
associated Mucins in 2005 by Professor Mall (Govender et ai., 2005) a question was 
raised by Professor Ingemar Carlstedt and Dr Annkatrin Herrmann about the nature of the 
band at the end ofthe gels for MUC2 in TB patients (Figure 4.7 and 4.8, lanes 7-11 and 
9-12 respectively). Dr Herrmann subsequently supplied us with an affinity purified 
LUM2-3 against MUC2 (Herrmann et ai., 1999) to confirm the presence of the above 
mentioned band. This did not work in our hands. In November of 2005, Dr John 
Sheehan visited our labs and suggested that the agarose gel, after electrophoresis, be 
incubated with 10mM DTT prior to blotting. This also failed to produce any results. The 
presence of MUC2 in TB will be further investigated as part of a PhD project as it could 
yield a wealth of information concerning diagnosis and susceptibility to TB. 
Unlike MUC2, MUC5AC and MUC5B did not appear as different glycoforms. Past 
literature has reported the presence of two MUC5B glycoforms in respiratory studies 
(Thornton et ai., 1997, Sheehan et ai., 1999 and Kirkham et al., 2002). Antibody 
detection of MUC5B in the controls and TB samples presented as dark smears that did 
not reveal different glycoforms. Identification of the glycoforms would probably require 
purification of reduced mucin preparations on a Mono Q anion exchange column as 
suggested by Thornton and Sheehan (2004). This might lead to similar findings as by 
Kirkham et al (2002) who discovered that the more acidic form of MUC5B was found in 
healthy airways in comparison to CF and COPD airways. We have just procured funding 
for an HPLC system. 
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The presence of the dominant gel forming mucins, MUC5AC and MUC5B has been 
established in control and TB groups. Furthermore the presence of MUC2 in TB adults 
and children suggests the influence ofa third gel forming mucin in TB. The implications 
of this are unknown but it is postulated that these mucins add to the increased viscosity 
and gel-like appearance of the TB sputum samples. TB is a recognized cause of 
bronchorrhea (Zar et ai., 1998) whereby patients produce up to a 100ml of mucus per 
day. It is conceivable that the increased mucus production is related not only to the 
hypersecretion of MUC5AC and MUC5B, MUC2 as welL The nature of the interaction 
between the three gel forming mucins is unknown and requires further investigation. 
CsCl purification of crude samples was not required prior to western blotting as the 
MUC5AC and MUC5B antibody detection of purified and crude samples presented with 
similar results. The use of crude material led to a substantial reduction in expense and 
time as CsCI purification is a lengthy, expensive procedure. CsCI purification was 
required prior to amino acid analysis. 
The amino acid analysis presented with a high combined value of glycine, threonine, 
serine, proline and alanine in the healthy control. This was indicative of a typical mucin 
amino acid profile. The glycine, threonine, serine, proline and alanine profile was lower 
in the PM and TB groups than in the volunteers. This was explained by differences in the 
secretion levels ofvarying mucin types depending on ones state of health. The individual 
serine, threonine and proline values did not dominate the amino acid composition; likely 
due to incomplete deglycosylation process prior to analysis. The PTS content and the 
combined serine and threonine content was slightly lower in the TB positive adults and 
children compared to the healthy volunteers. It is hypothesized that the TB bacterium has 
a greater affinity for the sugar side chains and that changes to the amino acids of the 
protein backbone would be secondary to that of the sugar side chains. Future studies 
should include the isolation and purification of individual mucins (MUC5AC, MUC5B 
and MUC2) from control and TB positive groups followed by amino acid analysis. This 
might lend insight into amino acid changes that are specific to the different mucin types. 
Sugar analysis was carried out but not reported due to incomplete data. It is planned for 
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the future to carry out an amino acid and sugar analysis of MUC5AC, MUC5B and 
MUC2 in the control and TB positive states. Amino acid sequencing would illustrate the 
sequence of the protein backbone and sugar analysis of the sialic acid and sulfate groups 
would provide information on the presence and difference between mucin gl ycoforms. 
Kirkham et al (2002) found that healthy airways house a more acidic form ofMUC5B in 
comparison to CF and COPD. 
Future analytical studies on lipid and DNA should be considered. The analysis of DNA 
during CsCI purification aids in determining the purity of the mucins hence the efficiency 
of the technique. Lipids are present in the sputum of patients who suffer from varying 
bronchial diseases; they exist at elevated levels in the secretion of cystic fibrosis patients 
(Slayter, 1987) and according to Woodward et al., (1982), "the contribution of lipid 
analysis to the overall architecture ofmucus secretions cannot be overlooked". 
Another future consideration would be quantitative western blotting as studies based on 
equivalent weight or concentration analyses would better illustrate the difference in 
mucin levels during the control and disease states. Such studies are challenging due to 
the difficulty in solubilising mucins but have been fruitful. MUC5AC and MUC5B, 
which were normalized on weight basis, were found at lower levels in CF sputum in 
comparison to normal airways (Rose and Voynow, 2006). Immunohistochemistry would 
also be a helpful tool in determining the presence and location of mucins in the TB 
positive tissue compared to controls. This might lend insight into the preSence and 
possible role of nonsecreted or membranous mucins in TB. 
8.2 The molecular study 
Mucus and mucin hypersecretion are a consequence of various acute and chronic 
respiratory disorders. The MUC genes that encode most mucins are known to house a 
great degree of length or sequence polymorphisms. Molecular studies have attempted to 
make a link between polymorphisms and susceptibility to the disease. A pilot study was 
carried out to determine if MUC2 and MUC5B polymorphisms present in European 
studies were found individuals in the Western Cape. 
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The MUC2 polymorphism for the homozygote C allele appeared in 6 of 20 (30%) TB 
positive individuals but did not feature in the TB negative individuals. Infact the TB 
positive group presented with a higher C allele frequency compared to the TB negative 
group. Although the sample size was too small to make inferences it does appear that the 
homozygote C allele could be associated with the TB positive group. If a correlation is 
made between the MUC2 polymorphism and the TB positive group within the Western 
Cape, it should be asked if the polymorphism suggests a susceptibility to TB and if and 
RFLP marker could be identified for TB. This would lead to screening for the marker, 
which would have great consequences not only for the individual but the country at large, 
as TB is a crippling disease within South Africa specifically in the Western Cape. 
Like Desseyn et al (1999) the intronic MUC5B polymorphism was identified in the 
Western Cape population but the TB study group presented with a larger allele frequency 
and a greater number of repeating units in comparison to that of DesseyIi et al (1999). 
The 10 repeating unit of the 59bp was absent in the European study yet appeared 
separately in a TB negative individual and the 8/8 allele combination appeared most 
frequently in the TB positive group compared to the TB negative group. Literature has 
illustrated the importance in the number of repeats of human MUC1 and rat Muc4 with 
respect to their anti-adhesive properties as it has been suggested that the number of 
repeats could be related to the physicochemical and rheological properties of mucus 
influencing bacterial adhesion to the cell surface (Escande et al., 2001). The number of 
59bp repeats could similarly influence the binding of the TB bacterium to hosts cell 
surface. This warrants further investigation within the Western Cape population. 
Escande et al (2001) illustrated, after RT-PCR sequencing of the 5' region of tracheal 
MUC5AC, that MUC5AC, MUC5B, MUC2 and the von Willebrand factor shared 
common features. Infact, together with MUC6, they are located on the same 
chromosome, llp15.5 (Rose and Voynow, 2006). Based on this similarity it would be 
advantageous to investigate polymorphisms within MUC5AC, MUC5B and MUC2, and 
their combined expression during TB, as pathogen by-products, immune mediators and 
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growth factors have been documented to upregulate mucin gene expression. By products 
of bacteria associated with cystic fibrosis (Pseudomonas aeruginosa) and COPD 
(Staphylococcus aureus) upregulate pathways that lead to the upregulation of MUC5AC 
and MUC2 (Rose and Voynow, 2006). 
Plans for a larger study should also consider relating the expression of the MUC protein 
glycofonns to the genetic polymorphisms. The biochemical study illustrated the presence 
of MUC2 glycofonns in the TB positive states ('possible', probable and definite TB) and 
its absence in the healthy volunteers. It would be interesting to detennine if the presence 
of MUC2 genetic polymorphism is associated with the varying glycofonns and if the 
level ofgene expression is related to depending on the glycofonn expression. 
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advantageous to investigate polymorphisms within MUC5AC, MUC5B and MUC2, and 
their combined expression during TB, as pathogen by-products, immune mediators and 
growth factors have been documented to upregulate mucin gene expression. By products 
of bacteria associated with cystic fibrosis (Pseudomonas aeroginosa) and COPD 
(Staphylococcus aureus) upregulate pathways that lead to the upregulation of MUC5AC 
and MUC2 (Rose and Voynow, 2006). 
Plans for a larger study should also consider relating the expression of the MUC protein 
glycoforms to the genetic polymorphisms. The biochemical study illustrated the presence 
of MUC2 glycoforms in the TB positive states ('possible', probable and definite TB) and 
its absence in the healthy volunteers. It would be interesting to determine if the presence 
of MUC2 genetic polymorphism is associated with the varying glycoforms and if the 
level of gene expression is related to depending on the glycoform expression. 
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APPENDIX A 
UNIVERSITY OF CAPE TOWN 
DEPARTMENT OF SURGERY 
MUCUS (SLIME) IN TUBERCULOSIS (TB) PROJECT: Information Leaflet 
Dear patient, 
We are doing a study on slime produced in your lungs that causes you to cough phlegm. 
We wish to find out what the slime is made of and whether it is different from the people 
who do not have a chest problem. The Nursing sister who has approached you will ask 
you to cough and 'spit' out the phlegm you produce into the jar she provides. 
We would also appreciate you allowing us to take a sample from the inside of your 
mouth. This will not be painful. We will use the sample to tell us about the genes you 
have for producing slime that you cough up. All samples will be coded and only the 
researcher will have access to your personal details. 
Please note: 
L 	 We will need to take your folder number (NOT YOUR NAME) from which we 
will get details of your age, gender and origin. All this information will be kept 
absolutely confidential and we promise not to use the samples for any other 
purpose than that we have described. 
2. 	 You have a right to say that you do not wish to take part in this study and can be 
assured that it will not affect the treatment you receive in hospitaL 
3. 	 If you agree to participate in this project now and then decide at a later time that 
you do not wish to continue, that is also fine. That decision will once again not 
affect your right to treatment and care 
4. 	 We will NOT test for HIV/AIDS. 
5. 	 The tests we mentioned cannot determine your complete genetic make-up. 
6. 	 It is possible that we will publish the findings of this study but your name will not 
be mentioned. 
Any questions, please ask the Nursing Sister who is taking the sample from you. If there 
are any questions you would like answered at a later date, please contact me at the 
number below. 
Professor A Mall 
Tel: 0214066186/6227 
92 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
REQUEST FOR MOLECULAR STUDIES (DNA) 
Research Laboratory 
Division of General Surgery 
OMB Groote Schuur Hospital 
UCT Medical School, Observatory 7925 
Tel: (021) 4066168/6227 Fax: (021) 448 6461 
Please fill in all the information requested: 
Surname: First name( s) 

Sex: M D F D Date of birth Year: Month:Day: 

Ethnic Origin: 
Contact address: Hospital/Clinic where samples are taken 
Town: 	 Fax: 
Tel: 
Reason for referral (clinical diagnosis): 
Additional disorders (apparent or previously treated): 
Smoker / Non-smoker. ..................................... .. 

For laboratory use onlv: 
DNA number .................... 

Date Received: YY DD: Computer Index No.: 

CONSENT FOR DNA ANALYSIS AND STORAGE 
1. 	 I, give permission that a 
mouth swab is taken for research purposes in the 
investigation of mucus (slime) in tuberculosis (TB). 
2. 	 I give permission that a portion of the samples be stored 
indefinitely for: 
a) 	 possible re-analysis; 
Research purposes, subject to the approval of the 
University of Cape Town Ethics Committee, 
provided that any information from such research 
will remain confidential. 
3. 	 I authorise 1do not authorise my doctor(s) (DELETE 
WHERE NOT APPLICABLE) to provide relevant clinical 
details to the researchers 
4. 	 I have been informed that findings made in this study could 
help in the management of tuberculosis (TB) in the future. 
ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME 
IN A LANGUAGE THAT I UNDERSTAND AND MY 
QUESTIONS ANSWERED BY: 
Please note 
that your HIV 
status is not 
recorded on 
this form. 
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APPENDIXB 
TB Mucin Study- GFJH 
Case Number 
Folder Number 
Initials 
DaB 
1. Sex 
2. Age 
_1__1__-
aMale a Female 
(for data below: yes= tick =1 no =no lick =2) 
3. WHO TB Diagnosis 
3.a 0 Definite 
3.b 0 Probable 
3.c 0 Possible 
4. TB diagnostic criteria 
4.a 0 Culture 
4.b 0 AFB+ (microscopy) 
4.c 0 ADA raised 

4.dOCXR 

4.e 0 Clinical improvement on TB Rx 
4.f 0 Nodes on Abd U/S 
4.g 0 Splenic lesions on Abd U/S 
5. Smoking History 
5.a 0 Never smoker 
5.b 0 Ex-smoker 
5.c 0 Current smoker 
6. Smoking Consumption 
6.a 0 Never smoker 
6.b 0 <10 pack yrs 
6.c 0 10 20 pack yrs 
6.d 0 >20 pack yrs 
7. Alcohol History 
7.a 0 Never drinker 
7.b 0 Current regular alcohol use 
7.c 0 Previous regular alcohol use 
8. Substance Abuse 
8.a 0 Mandrax 

8.bODagga 

8.c 0 Cocaine 
8.d OTic 
9. Diabetic: 
9.a 0 Known diabetic 
9.b 0 Requiring insulin 
9.c 0 Requiring oral medication 
9.d 0 Previous admission for poor control 
9.e Duration of admission: __ days 
10. HIV Status 
10.a 0 Negative 

lO.b 0 Not suspected 

lO.c 0 Suspected 

lO.d 0 Positive 

10.e 0 WHO II II 

IOJ 0 WHO III! IV 

10.g 0 On HAART 

lO.h Most recent CD4 count (if available) 
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11 Other Respiratory Disease 
ll.a 0 Bronchiectasis 
11.b 0 Mouth crackles 
11.c 0 Clubbing 

Il.d 0 Chronic sputum 

11.e 0 CXR features 
11.f OCOAD 
11.g 0 Chronic cough productive of cough >3112 for 2 years 
11.h 0 Smoking history> 20 pack years 
ll.i 0 Reduced FEVlI PVC 
11.j 0 Reversibility on bronchodilator therapy < 15 % (PEFR) 
II.k 0 CXR features 
11.1 0 Asthma 
11.m 0 Convincing history of continuous episodic SOB, cough, tight chest 
11.n 0 Known allergen! event precipitating bronchospasm 
11.0 0 Hx of atopy (allergic rhinitis! urticarial eczema) 
11.p 0 Reversibility spontaneousl removal of known precipitating allergen 
11.q 0 Reversibility on bronchodilator therapy> 15 % (PEFR) 
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